

# CITATION REPORT

List of articles citing

## Untangling the ErbB signalling network

DOI: 10.1038/35052073

Nature Reviews Molecular Cell Biology, 2001, 2, 127-37.

**Source:** <https://exaly.com/paper-pdf/33210337/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2313	Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus?. <b>2011</b> , 5, 220		2
2312	REVIEWS OF BOOKS. <b>1983</b> , 64, 98-99		
2311	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. <b>1992</b> , 34, 43		3
2310	gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. <b>2001</b> , 294, 2179-81		760
2309	Chemical inhibitors of protein kinases. <b>2001</b> , 101, 2541-72		289
2308	shibire's enhancer is cancer's suppressor. <b>2001</b> , 24, 625-6		6
2307	The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. <b>2001</b> , 37 Suppl 4, S3-8		1141
2306	Regulated intracellular ligand transport and proteolysis control EGF signal activation in Drosophila. <b>2001</b> , 107, 161-71		322
2305	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. <b>2001</b> , 1, 719-32		82
2304	Tyrosine kinase inhibitors-ZD1839 (Iressa). <b>2001</b> , 13, 491-8		127
2303	Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab). <b>2001</b> , 8, 316-20		11
2302	Signal transduction: multiple pathways, multiple options for therapy. <b>2001</b> , 19, 295-303		31
2301	The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. <b>2001</b> , 6, 393-406		141
2300	EGF receptors as transcription factors: ridiculous or sublime?. <b>2001</b> , 3, E209-11		28
2299	Heregulin-dependent translocation and hyperphosphorylation of ErbB-2. <b>2001</b> , 20, 3918-20		26
2298	The hunting of the Src. <i>Nature Reviews Molecular Cell Biology</i> , <b>2001</b> , 2, 467-75	48.7	499
2297	Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. <b>2001</b> , 93, 1830-2		78

2296	The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. <b>2001</b> , 154, 1245-58	82
2295	Mig-6 is a negative regulator of the epidermal growth factor receptor signal. <b>2001</b> , 382, 1649-62	117
2294	Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). <b>2001</b> , 93, 1852-7	725
2293	Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by <i>Neisseria meningitidis</i> . <b>2001</b> , 155, 133-43	106
2292	Endocytosis of epidermal growth factor receptor regulated by Grb2-mediated recruitment of the Rab5 GTPase-activating protein RN-tre. <b>2002</b> , 277, 50996-1002	46
2291	Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. <b>2002</b> , 1, 91-8	220
2290	Molecular Cytogenetics. <b>2002</b> ,	2
2289	Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. <b>2002</b> , 99, 3770-5	23
2288	Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. <b>2002</b> , 277, 8961-9	40
2287	Initiating oncogenic event determines gene-expression patterns of human breast cancer models. <b>2002</b> , 99, 6967-72	175
2286	A new mutator phenotype in breast cancer?. <b>2002</b> , 99, 3368-9	3
2285	Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. <b>2002</b> , 99, 8880-5	368
2284	Modeling the epidermal growth factor -- epidermal growth factor receptor l2 domain interaction: implications for the ligand binding process. <b>2002</b> , 19, 961-72	6
2283	Epidermal growth factor receptor dependence in human tumors: more than just expression?. <b>2002</b> , 7 Suppl 4, 31-9	379
2282	Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. <b>2002</b> , 277, 6318-23	237
2281	Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. <b>2002</b> , 13, 8-9	28
2280	Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest. <b>2002</b> , 277, 20618-24	33
2279	Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. <b>2002</b> , 277, 28468-73	53

2278	HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. <b>2002</b> , 117, 935-43	76
2277	Individual-based simulation of the clustering behaviour of epidermal growth factor receptors.. <b>2002</b> ,	1
2276	FISH detection of HER2 amplification in breast cancer. <b>2002</b> , 204, 353-67	1
2275	ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. <b>2002</b> , 22, 2204-19	108
2274	Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. <b>2002</b> , 13, 4029-44	114
2273	Autocrine loops with positive feedback enable context-dependent cell signaling. <b>2002</b> , 282, C545-59	97
2272	Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. <b>2002</b> , 22, 7279-90	232
2271	Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody(Trastuzumab).. <b>2002</b> , 35, 77-81	3
2270	Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. <b>2002</b> , 277, 46265-72	902
2269	Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity. <b>2002</b> , 275, 9-16	10
2268	Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation. <b>2002</b> , 280, 134-47	39
2267	Protein ectodomain shedding. <b>2002</b> , 102, 4627-38	209
2266	Resistance to trastuzumab: a necessary evil or a temporary challenge?. <b>2002</b> , 3, 247-57; discussion 258-9	54
2265	The EGF/ErbB receptor family and apoptosis. <b>2002</b> , 20, 1-15	91
2264	Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells. <b>2002</b> , 13, 1522-35	169
2263	Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor. <b>2002</b> , 41, 6338-45	74
2262	HER-targeted tyrosine-kinase inhibitors. <b>2002</b> , 63 Suppl 1, 6-16	44
2261	A new model for ductal carcinoma in situ suggests strategies for treatment. <b>2002</b> , 4, 176-8	5

2260	Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. <b>2002</b> , 115, 4251-62	154
2259	Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. <b>2002</b> , 110, 763-73	619
2258	Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. <b>2002</b> , 10, 283-94	326
2257	Trastuzumab: hopes and realities. <b>2002</b> , 3, 137-44	134
2256	Epidermal growth factor receptor tyrosine kinase inhibitors. <b>2002</b> , 2, 382-7	67
2255	Is There a Role for Monitoring Circulating HER2?. <b>2002</b> , 3, 136-137	11
2254	Smart drugs: tyrosine kinase inhibitors in cancer therapy. <b>2002</b> , 1, 117-23	423
2253	Biotechnologies and therapeutics: chromatin as a target. <b>2002</b> , 12, 233-42	21
2252	Comparison of thalamic populations in mammals and birds: expression of ErbB4 mRNA. <b>2002</b> , 57, 455-61	46
2251	Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology. <b>2002</b> , 4, 237-42	4
2250	Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. <b>2002</b> , 20, 2217-9	64
2249	Roles of Erbb family receptor tyrosine kinases and downstream signaling pathways in the control of cell growth and survival. <b>2002</b> , 7, d376-389	17
2248	ErbB receptor tyrosine kinase inhibitors as therapeutic agents. <b>2002</b> , 7, d1926	9
2247	The future of targeted therapy: combining novel agents. <b>2002</b> , 63 Suppl 1, 47-56	21
2246	Effects of epidermal growth factor on epinephrine-stimulated heart function in rodents. <b>2002</b> , 283, H1887-95	16
2245	Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. <b>2002</b> , 7, d376-89	136
2244	Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. <b>2002</b> , 29, 15-26	28
2243	c-erbB-2 in breast cancer: development of a clinically useful marker. <b>2002</b> , 29, 231-45	100

2242	Expression of target molecules in lung cancer: challenge for a new treatment paradigm. <b>2002</b> , 29, 2-8	7
2241	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. <b>2002</b> , 93, 79-98	253
2240	Signaling revealed by mapping molecular interactions. <b>2002</b> , 2, 169-186	11
2239	Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. <b>2002</b> , 2, 127-37	729
2238	A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. <b>2002</b> , 2, 93-5	43
2237	Amphiregulin is a mitogen for adult neural stem cells. <b>2002</b> , 69, 757-62	63
2236	Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. <b>2002</b> , 101, 390-4	17
2235	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. <b>2002</b> , 94, 1593-611	391
2234	Secretases as targets for beta-amyloid lowering drugs. <b>2002</b> , 56, 201-210	7
2233	Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. <b>2002</b> , 21, 7690-9	113
2232	Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. <b>2002</b> , 21, 6530-9	69
2231	Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. <b>2002</b> , 21, 6573-86	73
2230	Localization of p0071-interacting proteins, plakophilin-related armadillo-repeat protein-interacting protein (PAPIN) and ERBIN, in epithelial cells. <b>2002</b> , 21, 7042-9	39
2229	Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. <b>2002</b> , 21, 8442-52	69
2228	Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. <b>2002</b> , 21, 7524-32	108
2227	Tumour biology: herceptin acts as an anti-angiogenic cocktail. <b>2002</b> , 416, 279-80	562
2226	Pointed and Tramtrack69 establish an EGFR-dependent transcriptional switch to regulate mitosis. <b>2002</b> , 4, 976-80	65
2225	Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. <b>2002</b> , 8, 850-5	271

2224	Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. <i>Nature Reviews Molecular Cell Biology</i> , <b>2002</b> , 3, 673-84	48.7	583
2223	The dominance of the microenvironment in breast and ovarian cancer. <b>2002</b> , 12, 97-104		102
2222	The epidermal growth factor receptor: a new target for anticancer therapy. <b>2002</b> , 26, 109-64		50
2221	Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. <b>2002</b> , 21, 2407-17		178
2220	A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. <b>2002</b> , 21, 303-13		221
2219	Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. <b>2002</b> , 21, 4796-808		193
2218	Neuregulin signaling via erbB receptor assemblies in the nervous system. <b>2002</b> , 25, 67-77		29
2217	Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system. <b>2003</b> , 21, 149-65		42
2216	Epidermal Growth Factor (EGF) Receptor Signaling. <b>2003</b> , 549-556		
2215	Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. <b>2003</b> , 22, 301-7		30
2214	Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. <b>2003</b> , 82, 155-64		77
2213	Neuregulins and the neuromuscular system: 10 years of answers and questions. <b>2003</b> , 32, 619-47		84
2212	TACE is required for the activation of the EGFR by TGF-alpha in tumors. <b>2003</b> , 22, 1114-24		239
2211	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. <b>2003</b> , 8, 307-25		462
2210	[Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma]. <b>2003</b> , 42, 650-9		4
2209	Biologic directed therapies in gynecologic oncology. <b>2003</b> , 5, 459-67		3
2208	Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. <b>2003</b> , 30, 1348-56		23
2207	Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. <b>2003</b> , 443, 28-31		24

2206	EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. <b>2003</b> , 129, 250-1	4
2205	Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. <b>2003</b> , 129, 669-75	31
2204	RIPped out by presenilin-dependent gamma-secretase. <b>2003</b> , 15, 829-41	53
2203	Nuclear localization and possible functions of receptor tyrosine kinases. <b>2003</b> , 15, 143-8	141
2202	Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. <b>2003</b> , 13, 297-307	158
2201	The role of ubiquitylation in signaling by growth factors: implications to cancer. <b>2003</b> , 13, 29-40	60
2200	Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. <b>2003</b> , 3, 471-82	81
2199	Dysregulation of cellular signaling by HER2/neu in breast cancer. <b>2003</b> , 30, 38-48	91
2198	The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. <b>2003</b> , 30, 3-11	134
2197	The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. <b>2003</b> , 5 Suppl 1, S5-S10	2
2196	Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. <b>2003</b> , 5 Suppl 1, S11-7	8
2195	Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. <b>2003</b> , 66, 819-30	26
2194	Preclinical studies with Erlotinib (Tarceva). <b>2003</b> , 30, 15-24	64
2193	Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. <b>2003</b> , 43, 104-18	32
2192	Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. <b>2003</b> , 195, 139-50	117
2191	Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. <b>2003</b> , 196, 370-7	92
2190	Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. <b>2003</b> , 10, 629-34	21
2189	Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. <b>2003</b> , 13, 637-40	54



2188	Inhibition of erbB receptor family members protects HaCaT keratinocytes from ultraviolet-B-induced apoptosis. <b>2003</b> , 120, 483-8	19
2187	The great escape: another way for melanoma to leave physiological control?. <b>2003</b> , 121, xi-xii	
2186	The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. <b>2003</b> , 121, 802-12	36
2185	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. <b>2003</b> , 56, 142-9	34
2184	c-erbB-4/HER4: friend or foe?. <b>2003</b> , 200, 279-81	52
2183	The clinical evaluation of HER-2 status: which test to use?. <b>2003</b> , 199, 411-7	119
2182	Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. <b>2003</b> , 200, 290-7	468
2181	Ready to partner. <b>2003</b> , 10, 158-9	33
2180	Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. <b>2003</b> , 89, 899-906	70
2179	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. <b>2003</b> , 421, 756-60	1138
2178	Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. <b>2003</b> , 422, 322-6	310
2177	Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. <b>2003</b> , 22, 1557-67	32
2176	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. <b>2003</b> , 22, 2812-22	409
2175	Feedback inhibition by RALT controls signal output by the ErbB network. <b>2003</b> , 22, 4221-34	97
2174	Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in <i>Caenorhabditis elegans</i> . <b>2003</b> , 22, 5471-80	8
2173	Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. <b>2003</b> , 113, 936-9	39
2172	Cell biology: Just mix and patch. <b>2003</b> , 422, 267-8	7
2171	Development of potent monoclonal antibody auristatin conjugates for cancer therapy. <b>2003</b> , 21, 778-84	865

2170	Design of multivalent complexes using the barnase*barstar module. <b>2003</b> , 21, 1486-92	155
2169	Gefitinib. <b>2003</b> , 3, 556-557	8
2168	Issues and progress with protein kinase inhibitors for cancer treatment. <b>2003</b> , 2, 296-313	410
2167	Gefitinib. <b>2003</b> , 2, 515-6	82
2166	Lateral phosphorylation propagation: an aspect of feedback signalling?. <i>Nature Reviews Molecular Cell Biology</i> , <b>2003</b> , 4, 971-4	48.7 26
2165	El factor de crecimiento epidérmico cuarenta años después de su descubrimiento: de la bioquímica a la clínica. <b>2003</b> , 50, 334-344	
2164	Molecular dynamics, free energy, and SPR analyses of the interactions between the SH2 domain of Grb2 and ErbB phosphotyrosyl peptides. <b>2003</b> , 42, 5195-200	34
2163	Stress and radiation-induced activation of multiple intracellular signaling pathways. <b>2003</b> , 159, 283-300	407
2162	Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. <b>2003</b> , 4, 348-53	80
2161	Development of new agents for the treatment of advanced colorectal cancer. <b>2003</b> , 3, 154-64	4
2160	Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. <b>2003</b> , 370, 323-9	47
2159	Epidermal growth factor as a biologic switch in hair growth cycle. <b>2003</b> , 278, 26120-6	71
2158	Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. <b>2003</b> , 57, 447-51	36
2157	Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. <b>2003</b> , 5, 475-86	57
2156	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. <b>2003</b> , 21, 2787-99	1051
2155	Gefitinib (Iressa) trials in non-small cell lung cancer. <b>2003</b> , 41 Suppl 1, S23-8	31
2154	Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects. <b>2003</b> , 120, 811-22	60
2153	The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer. <b>2003</b> , 2, 143-5	4

2152	Role of PI 3-kinase and PIP3 in submandibular gland branching morphogenesis. <b>2003</b> , 255, 178-91	83
2151	Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. <b>2003</b> , 282, 121-31	33
2150	Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. <b>2003</b> , 284, 291-302	43
2149	UVB-induced apoptosis in normal human keratinocytes: role of the erbB receptor family. <b>2003</b> , 284, 316-27	19
2148	Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. <b>2003</b> , 285, 39-49	83
2147	The ErbB receptors and their role in cancer progression. <b>2003</b> , 284, 99-110	516
2146	An integrated model of epidermal growth factor receptor trafficking and signal transduction. <b>2003</b> , 85, 730-43	143
2145	HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. <b>2003</b> , 85, 2732-45	51
2144	A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. <b>2003</b> , 192, 67-74	39
2143	Molecular diagnostics for determination of HER2 status in breast cancer. <b>2003</b> , 9, 48-55	4
2142	Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. <b>2003</b> , 39, 1348-54	192
2141	EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. <b>2003</b> , 11, 507-17	565
2140	The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. <b>2003</b> , 11, 495-505	442
2139	An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. <b>2003</b> , 12, 541-52	693
2138	The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. <b>2003</b> , 6, 95-107	15
2137	Molecular biology in diagnostic histopathology. Part 3: signal transduction. <b>2003</b> , 9, 397-407	1
2136	The ErbB receptors and their role in cancer progression. <b>2003</b> , 103-114	1
2135	Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. <b>2003</b> , 5, 99-109	25

2134	Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?. <b>2004</b> , 6, 65-8	29
2133	Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. <b>2003</b> , 5, 96-100	40
2132	Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. <b>2003</b> , 278, 37610-21	67
2131	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. <b>2003</b> , 100, 8933-8	749
2130	HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. <b>2003</b> , 49, 219-29	60
2129	Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. <b>2003</b> , 100, 8281-6	202
2128	Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. <b>2003</b> , 278, 35781-90	142
2127	Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. <b>2003</b> , 532, 253-68	149
2126	HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. <b>2003</b> , 278, 44377-84	79
2125	Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. <b>2003</b> , 23, 5803-15	80
2124	A carboxyl-terminal mutation of the epidermal growth factor receptor alters tyrosine kinase activity and substrate specificity as measured by a fluorescence polarization assay. <b>2003</b> , 278, 26810-6	7
2123	Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. <b>2003</b> , 17, 1609-21	99
2122	Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. <b>2003</b> , 130, 5257-68	128
2121	Crossing the cancer cell membrane to improve clinical outcomes. <b>2003</b> , 8 Suppl 3, 1-4	1
2120	Developing inhibitors of the epidermal growth factor receptor for cancer treatment. <b>2003</b> , 95, 851-67	306
2119	Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. <b>2003</b> , 8, 576-86	58
2118	Signal events: Cell signal transduction and its inhibition in cancer. <b>2003</b> , 8 Suppl 3, 5-17	53
2117	Her-2/neuGene Amplification in Familial vs Sporadic Breast Cancer. <b>2003</b> , 120, 917-927	9

2116	Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. <b>2003</b> , 23, 8691-703	180
2115	Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. <b>2003</b> , 23, 2213-24	35
2114	Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. <b>2003</b> , 116, 4557-66	163
2113	Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes. <b>2003</b> , 116, 3749-60	48
2112	Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. <b>2003</b> , 278, 23343-51	136
2111	[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. <b>2003</b> , 18, 643-54	15
2110	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. <b>2003</b> , 12, 577-92	1
2109	Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. <b>2003</b> , 88, 796-802	102
2108	Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. <b>2003</b> , 3, 269-79	41
2107	Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. <b>2003</b> , 12, 1899-924	31
2106	Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. <b>2003</b> , 278, 20971-8	38
2105	The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. <b>2003</b> , 278, 23441-50	117
2104	Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. <b>2003</b> , 278, 31972-9	85
2103	Profiling receptor tyrosine kinase activation by using Ab microarrays. <b>2003</b> , 100, 9330-5	202
2102	Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?. <b>2003</b> , 21, 2227-9	43
2101	Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands. <b>2003</b> , 278, 12055-63	11
2100	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. <b>2003</b> , 21, 3798-807	1166
2099	Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. <b>2003</b> , 79, 547-59	50

2098	Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage. <b>2003</b> , 278, 4561-5	57
2097	Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM. <b>2003</b> , 278, 24951-9	28
2096	Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. <b>2003</b> , 278, 51408-14	62
2095	Neuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortex. <b>2003</b> , 100, 4251-6	174
2094	Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. <b>2003</b> , 130, 4515-25	97
2093	Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. <b>2003</b> , 23, 6243-54	88
2092	Aldosterone stimulates epidermal growth factor receptor expression. <b>2003</b> , 278, 43060-6	84
2091	Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. <b>2003</b> , 100, 2438-43	123
2090	Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging. <b>2003</b> , 2, 599-607	10
2089	Inhibiting Tyrosine Kinases: Successes and Limitations. <b>2003</b> , 2, 78-82	62
2088	Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. <b>2003</b> , 22, 1225	5
2087	Suppression of TNF-alpha mediated apoptosis by EGF in TNF-alpha sensitive human cervical carcinoma cell line. <b>2003</b> , 21, 31-9	9
2086	Glial/Neuronal/Endothelial interactions and the neuroendocrine control of GnRH secretion. <b>2003</b> , 31, 199-214	2
2085	A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. <b>2003</b> , 373, 451-63	188
2084	ErbB4 Signaling During Breast and Neural Development: Novel Genetic Models Reveal Unique ErbB4 Activities. <b>2003</b> , 2, 554-558	14
2083	HER-2/neu testing in breast cancer. <b>2003</b> , 120 Suppl, S53-71	19
2082	Mechanism of action of erbB tyrosine kinase inhibitors. <b>2003</b> , 137-145	0
2081	Chapter 23. Recent advances in antibody drug conjugates for cancer therapy. <b>2003</b> , 38, 229-237	6

2080	Targeting Retroviral Vectors Using Molecular Bridges. <b>2003</b> , 253-266	
2079	Imaging molecular interactions in cells by dynamic and static fluorescence anisotropy (rFLIM and emFRET). <b>2003</b> , 31, 1020-7	130
2078	Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. <b>2003</b> , 31, 1198-202	44
2077	Activated epidermal growth factor receptor (ErbB1) protects the heart against stress-induced injury in mice. <b>2003</b> , 285, R455-62	25
2076	Neuregulins: Functions, forms, and signaling strategies. <b>2003</b> , 15-31	2
2075	Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. <b>2003</b> , 284, C1149-55	78
2074	The deaf and the dumb. <b>2003</b> , 57-68	1
2073	Biomechanical stress-induced signaling in smooth muscle cells: an update. <b>2003</b> , 1, 41-58	52
2072	Role of Lipid Domains in EGF Receptor Signaling. <b>2003</b> , 323-326	
2071	Normal female sexual development requires neuregulin-erbB receptor signaling in hypothalamic astrocytes. <b>2003</b> , 23, 230-9	139
2070	Epidermal growth factor receptor. <b>2003</b> , 33-55	8
2069	Nuclear factor-kappa B activation promotes restitution of wounded intestinal epithelial monolayers. <b>2003</b> , 285, C1028-35	78
2068	ErbBs in mammary development. <b>2003</b> , 93-102	2
2067	Expression of neuregulin 1, a member of the epidermal growth factor family, is expressed as multiple splice variants in the adult human cornea. <b>2004</b> , 45, 3021-9	16
2066	Receptor tyrosine kinases and inhibitors in lung cancer. <b>2004</b> , 4, 589-604	28
2065	Cocoa procyanidins inhibit proliferation and angiogenic signals in human dermal microvascular endothelial cells following stimulation by low-level H <sub>2</sub> O <sub>2</sub> . <b>2004</b> , 229, 765-71	12
2064	Role of ErbB2 in Corneal Epithelial Wound Healing. <b>2004</b> , 45, 4277-83	44
2063	Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. <b>2004</b> , 44, 52-8	21

2062	. 2004,	8
2061	Genes That Control Cell Migration during Mouse Development. 317-330	1
2060	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. 2004, 19, 183-189	1
2059	Novel targeted agents in the treatment of lung cancer. 2004, 13, 609-29	2
2058	Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. 2004, 4, 5-17	37
2057	The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types. 2004, 145, 5177-84	32
2056	Principles of Molecular Oncology. 2004,	6
2055	Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?. 2004, 16 Suppl 4, 44-8	14
2054	Velvet, a dominant Egfr mutation that causes wavy hair and defective eyelid development in mice. 2004, 166, 331-40	56
2053	Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. 2004, 10, 7747-56	45
2052	Overcoming endocrine therapy resistance by signal transduction inhibition. 2004, 9 Suppl 3, 20-6	79
2051	Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. 2004, 10, 1344-53	106
2050	Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. 2004, 45, 813-20	120
2049	Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. 2004, 22, 3003-15	291
2048	HER1/EGFR targeting: refining the strategy. 2004, 9, 58-67	91
2047	Embryo-uterine interactions via the neuregulin family of growth factors during implantation in the mouse. 2004, 71, 2003-11	22
2046	Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. 2004, 22, 1180-7	171
2045	Tamoxifen: Dr. Jekyll and Mr. Hyde?. 2004, 96, 895-7	22



2044	Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. <b>2004</b> , 68, 1-27	61
2043	Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. <b>2004</b> , 15, 1557-67	168
2042	Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. <b>2004</b> , 24, 4613-26	104
2041	Role of EGFR transactivation in preventing apoptosis in <i>Pseudomonas aeruginosa</i> -infected human corneal epithelial cells. <b>2004</b> , 45, 2569-76	45
2040	Neuregulin signaling on glucose transport in muscle cells. <b>2004</b> , 279, 12260-8	54
2039	Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). <b>2004</b> , 10, 6476-86	73
2038	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. <b>2004</b> , 15, 5268-82	383
2037	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. <b>2004</b> , 10, 169-175	
2036	Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. <b>2004</b> , 64, 1460-7	58
2035	What are the real roles of different erbB proteins in Barrett's Esophagus. <b>2004</b> , 70, 93-4	1
2034	The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. <b>2004</b> , 64, 3538-44	32
2033	A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. <b>2004</b> , 10, 2986-96	69
2032	Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. <b>2004</b> , 10, 4383-8	71
2031	Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. <b>2004</b> , 165, 869-80	128
2030	Conservation of epidermal growth factor receptor function in the human parasitic helminth <i>Schistosoma mansoni</i> . <b>2004</b> , 279, 37407-14	87
2029	Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. <b>2004</b> , 279, 14909-16	73
2028	Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. <b>2004</b> , 279, 25838-48	34
2027	Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. <b>2004</b> , 3, 327-44	252

2026	Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. <b>2004</b> , 181, 179-90	25
2025	Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. <b>2004</b> , 24, 8907-16	82
2024	Imaging phosphorylation dynamics of the epidermal growth factor receptor. <b>2004</b> , 279, 36972-81	71
2023	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). <b>2004</b> , 13, 3029-43	139
2022	MAP Kinase Signaling Protocols. <b>2004</b> ,	
2021	Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. <b>2004</b> , 10, 2512-24	72
2020	Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. <b>2004</b> , 24, 581	1
2019	Gefitinib (Iressa[ZD1839]), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. <b>2004</b> , 25, 203	5
2018	The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention. <b>2004</b> , 3, 50-59	110
2017	PPARgamma signaling: one size fits all?. <b>2004</b> , 3, 1352-4	5
2016	Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. <b>2004</b> , 15, 33-7	30
2015	Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. <b>2004</b> , 22, 4737-45	58
2014	Signaling by growth factor receptors. <b>2004</b> , 250, 177-202	1
2013	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. <b>2004</b> , 64, 3958-65	493
2012	Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. <b>2004</b> , 10, 3885-96	142
2011	Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. <b>2004</b> , 164, 769-79	795
2010	Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. <b>2004</b> , 279, 28970-8	93
2009	Bipartite inhibition of Drosophila epidermal growth factor receptor by the extracellular and transmembrane domains of Kekk1. <b>2004</b> , 167, 187-202	14

2008	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. <b>2004</b> , 64, 5355-62	343
2007	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. <b>2004</b> , 101, 10137-42	367
2006	Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. <b>2004</b> , 64, 2601-9	86
2005	Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004. <b>2004</b> , 10, 428-32	16
2004	The Na <sup>+</sup> /H <sup>+</sup> exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. <b>2004</b> , 15, 5470-80	87
2003	Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. <b>2004</b> , 131, 5551-60	11
2002	Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. <b>2004</b> , 279, 4339-45	90
2001	Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. <b>2004</b> , 279, 24505-13	130
2000	Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. <b>2004</b> , 101, 13921-6	64
1999	Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. <b>2004</b> , 90, 236-44	53
1998	Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. <b>2004</b> , 90, 173-81	37
1997	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. <b>2004</b> , 91, 208-12	180
1996	From chemoprevention to chemotherapy: common targets and common goals. <b>2004</b> , 13, 1327-38	128
1995	Epidermal growth factor receptor signaling in tissues. <b>2004</b> , 24, 53-61	5
1994	Trastuzumab-based combination therapy for breast cancer. <b>2004</b> , 5, 81-96	39
1993	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. <b>2004</b> , 10, 6487-501	257
1992	Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. <b>2004</b> , 279, 50004-11	52
1991	Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. <b>2004</b> , 24, 25-35	105

1990 Abstracts. **2004**, 22, 1-104

1989	HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. <b>2004</b> , 43, 80-6	29
1988	Extracellular signal-regulated kinase/mitogen-activated protein kinases block internalization of delta-opioid receptors. <b>2004</b> , 309, 776-85	30
1987	Targeting protein kinases in cancer therapy: a success?. <b>2004</b> , 4, 1113-24	41
1986	Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. <b>2004</b> , 22, 984-93	221
1985	Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. <b>2004</b> , 96, 1117-9	34
1984	Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. <b>2004</b> , 287, C807-13	19
1983	Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution. <b>2004</b> , 287, G1213-9	34
1982	Cetuximab (Erbix)---an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. <b>2004</b> , 58, 970-6	27
1981	Membrane distribution of epidermal growth factor receptors in cells expressing different gangliosides. <b>2004</b> , 271, 2428-37	26
1980	Molecular medicine: a clinician's primer on microarrays. <b>2004</b> , 34, 565-9	1
1979	The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta. <b>2004</b> , 91, 1302-11	38
1978	Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. <b>2004</b> , 91, 1358-68	48
1977	Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. <b>2004</b> , 24, 687-95	16
1976	The neuronal nitric oxide synthase is upregulated in mouse skin repair and in response to epidermal growth factor in human HaCaT keratinocytes. <b>2004</b> , 123, 132-9	32
1975	Cholesterol depletion upregulates involucrin expression in epidermal keratinocytes through activation of p38. <b>2004</b> , 123, 564-73	59
1974	Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. <b>2004</b> , 22, 198-203	699
1973	Memo mediates ErbB2-driven cell motility. <b>2004</b> , 6, 515-22	93

1972	Selecting the right patient for tumor therapy. <b>2004</b> , 10, 577-8	21
1971	Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain. <b>2004</b> , 7, 1319-28	215
1970	Gefitinib--a novel targeted approach to treating cancer. <b>2004</b> , 4, 956-65	283
1969	Cancer. <b>2004</b> , 3, S6-S10	1
1968	Cetuximab. <b>2004</b> , 3, 549-50	104
1967	Development of TGF-beta signalling inhibitors for cancer therapy. <b>2004</b> , 3, 1011-22	452
1966	LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. <b>2004</b> , 23, 3270-81	230
1965	Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. <b>2004</b> , 5, 1165-70	116
1964	Gene expression profiling of ErbB receptor and ligand-dependent transcription. <b>2004</b> , 23, 1428-38	17
1963	Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. <b>2004</b> , 23, 2057-70	331
1962	Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase. <b>2004</b> , 23, 5023-31	11
1961	HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. <b>2004</b> , 90, 2344-8	176
1960	Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha. <b>2004</b> , 91, 1955-63	5
1959	Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. <b>2004</b> , 91, 2034-41	66
1958	Argos inhibits epidermal growth factor receptor signalling by ligand sequestration. <b>2004</b> , 430, 1040-4	114
1957	Enlightened receptor dynamics. <b>2004</b> , 22, 169-70	12
1956	A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. <b>2004</b> , 12, 2265-75	57
1955	Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. <b>2004</b> , 285, 99-109	4

1954	'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). <b>2004</b> , 14, 33-40	55
1953	Oncogenic growth factor receptors: implications for signal transduction therapy. <b>2004</b> , 14, 262-70	110
1952	Simulating complex intracellular processes using object-oriented computational modelling. <b>2004</b> , 86, 379-406	17
1951	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. <b>2004</b> , 5, 317-28	837
1950	A new therapeutic antibody masks ErbB2 to its partners. <b>2004</b> , 5, 299-301	67
1949	Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. <b>2004</b> , 5, 411-5	68
1948	Targeting the HER-kinase axis in cancer. <b>2004</b> , 31, 9-20	53
1947	Molecular approach to breast cancer treatment. <b>2004</b> , 31, 6-13	59
1946	Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. <b>2004</b> , 5, 52-8; discussion 59-62	109
1945	Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. <b>2004</b> , 6 Suppl 1, S35-42	8
1944	Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha. <b>2004</b> , 68, 2221-7	5
1943	Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. <b>2004</b> , 155, 108-18	18
1942	Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. <b>2004</b> , 5, 565-74	29
1941	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. <b>2004</b> , 5, 525-31	82
1940	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. <b>2004</b> , 6, 251-61	237
1939	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. <b>2004</b> , 6, 459-69	443
1938	HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?. <b>2004</b> , 6, 427-8	21
1937	Endocytosis and cancer. <b>2004</b> , 16, 156-61	92

1936	Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. <b>2004</b> , 14, 1124-9	64
1935	Tyrosine kinase receptors as attractive targets of cancer therapy. <b>2004</b> , 50, 23-38	140
1934	Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice. <b>2004</b> , 9, 55-66	21
1933	In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. <b>2004</b> , 21, 1670-9	11
1932	Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target. <b>2004</b> , 1030, 150-7	18
1931	Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. <b>2004</b> , 108, 135-42	110
1930	Ciblage du r�cepteur aux facteurs de croissance �ithliaux (REGF) par les inhibiteurs de tyrosine kinase et applications dans les cancers colorectaux. <b>2004</b> , 6, 41-45	
1929	Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. <b>2004</b> , 11, 38-41	25
1928	Utility of immunohistochemistry in breast cancer practice. <b>2004</b> , 11, 334-8	14
1927	The HER receptor family: a rich target for therapeutic development. <b>2004</b> , 58, 932-40	75
1926	Review of epidermal growth factor receptor biology. <b>2004</b> , 59, 21-6	859
1925	[Designer-drugs in tumor treatment]. <b>2004</b> , 45 Suppl 1, S38-47	
1924	Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. <b>2004</b> , 61, 1157-66	19
1923	Novel actions of tyrphostin AG 879: inhibition of RAF-1 and HER-2 expression combined with strong antitumoral effects on breast cancer cells. <b>2004</b> , 61, 2624-31	10
1922	The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. <b>2004</b> , 5, 393-403	11
1921	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. <b>2004</b> , 49, 91-107	33
1920	Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. <b>2004</b> , 204, 317-25	78
1919	Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. <b>2004</b> , 59, 157-66	48

1918	Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. <b>2004</b> , 39, 288-97	94
1917	Role of the aging vasculature and Erb B-2 signaling in epidermal growth factor-dependent intravasation of breast carcinoma cells. <b>2004</b> , 101, 198-205	6
1916	Multiple personalities of neuregulin gene family members. <b>2004</b> , 472, 134-9	18
1915	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. <b>2004</b> , 108, 334-41	170
1914	Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. <b>2004</b> , 111, 86-95	46
1913	Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts. <b>2004</b> , 112, 738-46	46
1912	Role of HER receptors family in development and differentiation. <b>2004</b> , 200, 343-50	168
1911	Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. <b>2004</b> , 41, 164-78	65
1910	Ensemble and single particle photophysical properties (two-photon excitation, anisotropy, FRET, lifetime, spectral conversion) of commercial quantum dots in solution and in live cells. <b>2004</b> , 65, 169-79	116
1909	Signal transduction and oncogenesis by ErbB/HER receptors. <b>2004</b> , 58, 903-13	300
1908	Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. <b>2004</b> , 58, 966-71	140
1907	Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. <b>2004</b> , 58, 941-9	44
1906	4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. <b>2004</b> , 39, 1001-11	21
1905	Inhibition of Hsp90: a new strategy for inhibiting protein kinases. <b>2004</b> , 1697, 233-42	115
1904	ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. <b>2004</b> , 43, 453-9	18
1903	Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. <b>2004</b> , 22, 89-95	86
1902	ErbB2 is required for ductal morphogenesis of the mammary gland. <b>2004</b> , 101, 17138-43	65
1901	The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. <b>2004</b> , 55, 433-57	170



1900	Axonal neuregulin-1 regulates myelin sheath thickness. <b>2004</b> , 304, 700-3	720
1899	EGF-like growth factors as mediators of LH action in the ovulatory follicle. <b>2004</b> , 303, 682-4	781
1898	Oncogenic growth factor receptors: implications for signal transduction therapy. <b>2004</b> ,	
1897	[Targeted therapies in thoracic oncology]. <b>2004</b> , 21, 527-37	1
1896	Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. <b>2004</b> , 6, 705-12	20
1895	Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. <b>2004</b> ,	
1894	Targeted therapies for cancer [from tamoxifen to gefitinib (Iressa)] <b>2004</b> , 1, 411-416	2
1893	STAT proteins as novel targets for cancer drug discovery. <b>2004</b> , 8, 409-22	233
1892	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. <b>2004</b> , 46, 247-54	50
1891	Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer. <b>2004</b> , 4, 107-23	4
1890	Targeted therapy in breast cancer: the HER-2/neu gene and protein. <b>2004</b> , 3, 379-98	226
1889	ErbB receptors: directing key signaling networks throughout life. <b>2004</b> , 44, 195-217	486
1888	Essential function for ErbB3 in breast cancer proliferation. <b>2004</b> , 6, 137-9	8
1887	Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. <b>2004</b> , 6, R246-51	108
1886	Structural analysis of autoinhibition in the Ras activator Son of sevenless. <b>2004</b> , 119, 393-405	216
1885	The role of epidermal growth factor and its receptors in mammalian CNS. <b>2004</b> , 15, 147-56	166
1884	Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. <b>2004</b> , 15, 337-51	72
1883	ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. <b>2004</b> , 569, 332-6	112

1882	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. <b>2004</b> , 313, 709-15	27
1881	The ErbB/HER receptor protein-tyrosine kinases and cancer. <b>2004</b> , 319, 1-11	309
1880	EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. <b>2004</b> , 292, 201-8	69
1879	Lysophosphatidic acid regulates murine blastocyst development by transactivation of receptors for heparin-binding EGF-like growth factor. <b>2004</b> , 296, 317-26	66
1878	EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation. <b>2004</b> , 297, 272-84	14
1877	Mapping nucleolar and spliceosome localization sequences of neuregulin1-beta3. <b>2004</b> , 299, 110-8	21
1876	Neuregulin-1 reduces ischemia-induced brain damage in rats. <b>2004</b> , 25, 935-44	63
1875	Angiogenesis and hepatocellular carcinoma. <b>2004</b> , 41, 864-80	286
1874	Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. <b>2004</b> , 342, 539-50	113
1873	Web-based tools for mining the NCI databases for anticancer drug discovery. <b>2004</b> , 44, 249-57	25
1872	Medulloblastoma: signalling a change in treatment. <b>2004</b> , 5, 209-18	242
1871	Inhibition of ErbB1 and ErbB2 by Lapatinib Ditosylate, a Dual Kinase Inhibitor: Promising Activity in Pretreated Advanced Breast Cancer. <b>2004</b> , 4, 398-400	5
1870	On the road to immortality: hTERT upregulation in cancer cells. <b>2004</b> , 564, 9-13	94
1869	Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. <b>2004</b> , 9, 361-77	150
1868	Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. <b>2004</b> , 279, 12988-96	54
1867	Heart valve development: endothelial cell signaling and differentiation. <b>2004</b> , 95, 459-70	504
1866	Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. <b>2004</b> , 72, 95-101	36
1865	The role of EGFR inhibitors in nonsmall cell lung cancer. <b>2004</b> , 16, 130-5	76

1864	Active and inactive conformations of the epidermal growth factor receptor. <b>2004</b> , 32, 742-5	52
1863	Biology of the epidermal growth factor receptor family. <b>2004</b> , 119, 1-13	28
1862	Cytometry of fluorescence resonance energy transfer. <b>2004</b> , 75, 105-52	25
1861	Antiepidermal Growth Factor Receptor Antibody: Immunohistochemistry. <b>2005</b> , 3, 79-92	
1860	3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. <b>2005</b> , 4, 333-338	
1859	Polypeptide growth factors and their receptors. <b>2005</b> , 126, 1-14	
1858	Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. <b>2005</b> , 28, 236-44	21
1857	Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. <b>2005</b> , 29, 1505-11	39
1856	ADAM10. <b>2005</b> , 85-121	5
1855	Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. <b>2005</b> , 28, 631-3	2
1854	Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. <b>2005</b> , 433-450	0
1853	ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. <b>2005</b> , 15, 21-8	42
1852	Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. <b>2005</b> , 13, 5613-22	35
1851	New dual inhibitors of EGFR and HER2 protein tyrosine kinases. <b>2005</b> , 15, 4774-9	39
1850	The dilemma of the strive for apoptosis in oncology: mind the heart. <b>2005</b> , 53, 101-13	9
1849	Cytoplasmic/nuclear shuttling and tumor progression. <b>2005</b> , 1059, 11-5	30
1848	Targeting ligand cleavage to inhibit the ErbB pathway in cancer. <b>2005</b> , 1059, 56-60	3
1847	Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. <b>2005</b> , 23, 39-49	95

1846	2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. <b>2005</b> , 104, 2701-8	64
1845	A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. <b>2005</b> , 310, 1646-53	443
1844	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. <b>2005</b> , 16, 359-71	158
1843	Hyposmolarity-induced ErbB4 phosphorylation and its influence on the non-receptor tyrosine kinase network response in cultured cerebellar granule neurons. <b>2005</b> , 93, 1189-98	20
1842	The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. <b>2005</b> , 25, 69-78	21
1841	Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. <b>2005</b> , 95, 982-6	45
1840	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. <b>2005</b> , 21, 321-39	39
1839	Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. <b>2005</b> , 145, 829-36	36
1838	ERBB receptors and cancer: the complexity of targeted inhibitors. <b>2005</b> , 5, 341-54	2593
1837	Erlotinib hydrochloride. <b>2005</b> , 4, 13-4	142
1836	ADAMs: key components in EGFR signalling and development. <i>Nature Reviews Molecular Cell Biology</i> , <b>2005</b> , 6, 32-43	48.7 880
1835	Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. <i>Nature Reviews Molecular Cell Biology</i> , <b>2005</b> , 6, 112-26	48.7 709
1834	The Cbl interactome and its functions. <i>Nature Reviews Molecular Cell Biology</i> , <b>2005</b> , 6, 907-18	48.7 319
1833	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. <b>2005</b> , 24, 616-26	50
1832	Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. <b>2005</b> , 24, 1847-59	67
1831	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. <b>2005</b> , 24, 3002-10	101
1830	Identification of proteolytic fragments from ErbB-2 that induce apoptosis. <b>2005</b> , 24, 3906-13	9
1829	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. <b>2005</b> , 24, 4540-8	93

1828	Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. <b>2005</b> , 24, 5589-605	63
1827	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. <b>2005</b> , 24, 6213-21	222
1826	Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. <b>2005</b> , 24, 6564-73	98
1825	Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. <b>2005</b> , 24, 6502-15	17
1824	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <b>2005</b> , 24, 7281-9	57
1823	Genes that mediate breast cancer metastasis to lung. <b>2005</b> , 436, 518-24	2242
1822	Constitutive expression of epidermal growth factor receptors on normal human melanocytes. <b>2005</b> , 125, 392-4	11
1821	EGF receptor inhibition: attacks on multiple fronts. <b>2005</b> , 7, 287-8	35
1820	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. <b>2005</b> , 8, 287-97	348
1819	erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish. <b>2005</b> , 15, 513-24	251
1818	Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. <b>2005</b> , 70, 1035-47	105
1817	Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. <b>2005</b> , 1038, 171-82	52
1816	The epidermal growth factor receptor as a target for colorectal cancer therapy. <b>2005</b> , 32, 52-60	78
1815	The role of cetuximab in the therapy of previously treated advanced colorectal cancer. <b>2005</b> , 32, S55-8	6
1814	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. <b>2005</b> , 32, S59-62	27
1813	Molecular mechanisms in cancer: what should clinicians know?. <b>2005</b> , 32, 2-4	15
1812	N-methyl-N'-nitro-N-nitrosoguanidine interferes with the epidermal growth factor receptor-mediated signaling pathway. <b>2005</b> , 570, 175-84	15
1811	Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data. <b>2005</b> , 6, 109	16

1810	Laminin-1 and epidermal growth factor family members co-stimulate fetal pancreas cell proliferation and colony formation. <b>2005</b> , 73, 45-9	20
1809	Glycoprotein contributions to mammary gland and mammary tumor structure and function: roles of adherens junctions, ErbBs and membrane MUCs. <b>2005</b> , 96, 914-26	24
1808	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <b>2005</b> , 113, 109-15	139
1807	Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. <b>2005</b> , 113, 689-98	31
1806	Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. <b>2005</b> , 116, 359-67	115
1805	Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. <b>2005</b> , 104, 1391-7	121
1804	Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. <b>2005</b> , 67, 161-71	16
1803	Studies on epidermal growth factor receptor signaling in vertebrate limb patterning. <b>2005</b> , 233, 288-300	20
1802	Gold Nanocages: Engineering Their Structure for Biomedical Applications. <b>2005</b> , 17, 2255-2261	520
1801	Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: synthesis of <sup>18</sup> F-Iressa and related molecular probes. <b>2005</b> , 48, 829-843	40
1800	Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. <b>2005</b> , 79, 584-97	84
1799	Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. <b>2005</b> , 32, 771-7	9
1798	Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). <b>2005</b> , 181, 197-204	29
1797	[Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy]. <b>2005</b> , 53, 285-97; quiz 298	1
1796	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. <b>2005</b> , 83, 976-83	25
1795	Clinical significance of EGFR amplification and the aberrant EGFRVIII transcript in conventionally treated astrocytic gliomas. <b>2005</b> , 83, 917-26	85
1794	Blockade of epidermal growth factor receptor (EGFR) activity. <b>2005</b> , 53, 179-92	17
1793	The expression of neuregulin and erbB receptors in human skeletal muscle: effects of progressive resistance training. <b>2005</b> , 94, 371-5	19

1792	Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. <b>2005</b> , 131, 49-59	5
1791	Molecular mechanisms in Schwann cell survival and death during peripheral nerve development, injury and disease. <b>2005</b> , 7, 151-67	5
1790	Second-line therapy for advanced colorectal cancer. <b>2005</b> , 1, 7-12	
1789	Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor. <b>2005</b> , 7, 123-8	3
1788	The effect of RNAi-mediated gene silencing on her-2/neu gene expression in lung adenocarcinoma cells. <b>2005</b> , 17, 84-89	1
1787	Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. <b>2005</b> , 23, 391-409	78
1786	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. <b>2005</b> , 90, 157-63	76
1785	Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. <b>2005</b> , 91, 187-201	73
1784	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. <b>2005</b> , 92, 1-9	29
1783	Roles for neuregulins in human cancer. <b>2004</b> , 21, 665-84	40
1782	Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. <b>2005</b> , 205, 522-9	50
1781	Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4. <b>2005</b> , 59, 742-56	21
1780	Monoclonal Antibody Strategies for Targeting HER2. <b>2005</b> , 627-645	
1779	Novel (Bio)chemical and (Photo)physical Probes for Imaging Living Cells. <b>2005</b> , 99-118	
1778	Targeting of the EGFR As a Modulator of Cancer Chemotherapy. <b>2005</b> , 1-26	2
1777	EGFR network. <b>2005</b> ,	
1776	Akt activation is necessary for growth factor-induced trafficking of functional K(Ca) channels in developing parasympathetic neurons. <b>2005</b> , 93, 1174-82	48
1775	Novel Single Cell Fluorescence Approaches in the Investigation of Signaling at the Cellular Level. <b>2005</b> , 33-70	1

1774	The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. <b>2005</b> , 2, 301-315	3
1773	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. <b>2005</b> , 65, 1459-70	249
1772	Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. <b>2005</b> , 16, 273-8	505
1771	Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser780 and Ser795 is mediated by ERK1/2 in small intestine epithelial cells. <b>2005</b> , 280, 35992-8	49
1770	Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. <b>2005</b> , 289, H660-6	87
1769	An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. <b>2005</b> , 126, 41-53	105
1768	Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. <b>2005</b> , 5, 83-102	31
1767	Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. <b>2005</b> , 11, 1131-8	113
1766	Critical function for ADAM9 in mouse prostate cancer. <b>2005</b> , 65, 9312-9	93
1765	Cetuximab. <b>2005</b> , Suppl, S10-1	57
1764	Transforming growth factor {beta} (TGF- $\beta$ )-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF- $\beta$ function. <b>2005</b> , 25, 4703-15	72
1763	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. <b>2005</b> , 23, 5305-13	548
1762	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. <b>2005</b> , 280, 30392-9	203
1761	Epidermal Growth Factor. <b>2005</b> ,	
1760	Induction of human NF-IL6beta by epidermal growth factor is mediated through the p38 signaling pathway and cAMP response element-binding protein activation in A431 cells. <b>2005</b> , 16, 3365-76	32
1759	Heregulin induces glial cell line-derived neurotrophic growth factor-independent, non-branching growth and differentiation of ureteric bud epithelia. <b>2005</b> , 280, 42181-7	22
1758	The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. <b>2005</b> , 102, 15024-9	142
1757	G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. <b>2005</b> , 280, 26592-9	101



1756	Epidermal growth factor family members: endogenous mediators of the ovulatory response. <b>2005</b> , 146, 77-84	245
1755	Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. <b>2005</b> , 65, 1384-93	153
1754	Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha. <b>2005</b> , 65, 6120-9	74
1753	Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. <b>2005</b> , 65, 6801-10	59
1752	Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. <b>2005</b> , 289, H1153-60	98
1751	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. <b>2005</b> , 16, 538-48	39
1750	beta-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. <b>2005</b> , 280, 32157-67	42
1749	Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. <b>2005</b> , 11, 5300-9	87
1748	Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle. <b>2005</b> , 53, 87-91	25
1747	Inhibitors of growth factor signalling. <b>2005</b> , 12 Suppl 1, S183-7	43
1746	Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. <b>2005</b> , 23, 2534-43	336
1745	Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors. <b>2005</b> , 170, 619-26	191
1744	Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. <b>2005</b> , 23, 5560-7	213
1743	Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. <b>2005</b> , 65, 6789-800	114
1742	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. <b>2005</b> , 1, 449-60	17
1741	Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. <b>2005</b> , 16, 189-94	130
1740	In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. <b>2005</b> , 4, 1125-32	11
1739	Epidermal growth factor receptor inhibition by tyrphostin 51 induces apoptosis in luteinized granulosa cells. <b>2005</b> , 90, 469-73	14

1738	Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. <b>2005</b> , 1, 235-45	12
1737	Betacellulin overexpression in transgenic mice causes disproportionate growth, pulmonary hemorrhage syndrome, and complex eye pathology. <b>2005</b> , 146, 5237-46	48
1736	Stathmin expression modulates migratory properties of GN-11 neurons in vitro. <b>2005</b> , 146, 1825-34	32
1735	A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. <b>2005</b> , 65, 3257-63	84
1734	ADAM 17. <b>2005</b> , 171-197	3
1733	Epidermal growth factor receptor inhibitors in cancer treatment. <b>2005</b> , 1, 221-34	49
1732	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. <b>2005</b> , 5, 727-35	2
1731	Cetuximab in the treatment of colorectal cancer. <b>2005</b> , 1, 173-81	13
1730	Erlotinib hydrochloride. <b>2005</b> , 4, S14-S15	18
1729	Cdc2-mediated inhibition of epidermal growth factor activation of the extracellular signal-regulated kinase pathway during mitosis. <b>2005</b> , 280, 24524-31	29
1728	Genetic profiling of human hepatocellular carcinoma. <b>2005</b> , 25, 125-32	46
1727	Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. <b>2005</b> , 33, 490-9	29
1726	Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. <b>2005</b> , 23, 5578-87	337
1725	Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. <b>2005</b> , 4, 356-76	110
1724	ERBB2 in pediatric cancer: innocent until proven guilty. <b>2005</b> , 10, 508-17	25
1723	Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. <b>2005</b> , 280, 6157-69	56
1722	Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. <b>2005</b> , 280, 8503-12	71
1721	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. <b>2005</b> , 102, 1915-20	204

1720	Overexpression of the epidermal growth factor receptor confers migratory properties to nonmigratory postnatal neural progenitors. <b>2005</b> , 25, 11092-106	92
1719	Fusion to Listeriolysin O and delivery by <i>Listeria monocytogenes</i> enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. <b>2005</b> , 175, 3663-73	96
1718	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. <b>2005</b> , 23, 2502-12	302
1717	Epidermal growth factor-dependent phosphorylation of the GGA3 adaptor protein regulates its recruitment to membranes. <b>2005</b> , 25, 7988-8000	25
1716	ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. <b>2005</b> , 280, 24175-80	38
1715	WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. <b>2005</b> , 65, 6764-72	168
1714	Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. <b>2005</b> , 11, 1704-12	113
1713	Recycling of cell surface pro-transforming growth factor- $\alpha$ regulates epidermal growth factor receptor activation. <b>2005</b> , 280, 36970-7	7
1712	Lineage tracing and characterization of insulin-secreting cells generated from adult pancreatic acinar cells. <b>2005</b> , 102, 15116-21	224
1711	Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable <i>Haemophilus influenzae</i> -induced Toll-like receptor 2 expression via an Src-dependent p38 mitogen-activated protein kinase signaling pathway. <b>2005</b> , 280, 36185-94	49
1710	A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. <b>2005</b> , 280, 4656-62	42
1709	Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. <b>2005</b> , 25, 7734-42	216
1708	The ErbB4 neuregulin receptor mediates suppression of oligodendrocyte maturation. <b>2005</b> , 25, 5757-62	55
1707	ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. <b>2005</b> , 65, 6967-75	45
1706	Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. <b>2005</b> , 4, 1686-96	227
1705	Impact of EGFR expression on colorectal cancer patient prognosis and survival. <b>2005</b> , 16, 102-8	279
1704	Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. <b>2005</b> , 280, 24428-34	77
1703	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. <b>2005</b> , 11, 8686-98	451

1702	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. <b>2005</b> , 10, 855-74	8
1701	Abstracts. <b>2005</b> , 23, 1-117	
1700	Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. <b>2005</b> , 280, 1321-6	36
1699	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). <b>2005</b> , 65, 3328-35	313
1698	Impact of molecular pathology on the clinical management of lung cancer. <b>2005</b> , 72, 229-32	4
1697	Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. <b>2005</b> , 25, 9082-91	17
1696	Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. <b>2005</b> , 10, 282-91	35
1695	Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. <b>2005</b> , 65, 6534-42	107
1694	Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. <b>2005</b> , 118, 3869-81	82
1693	Therapeutic targeting of receptor tyrosine kinases in lung cancer. <b>2005</b> , 9, 533-59	20
1692	Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. <b>2005</b> , 11, 2163-8	115
1691	Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. <b>2005</b> , 11, 5572-80	33
1690	Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. <b>2005</b> , 179, 66-72	62
1689	Systems-level questions in Drosophila oogenesis. <b>2005</b> , 152, 276-84	12
1688	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. <b>2005</b> , 102, 11858-63	74
1687	ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. <b>2005</b> , 280, 1826-37	83
1686	Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. <b>2005</b> , 280, 8875-83	179
1685	Phosphotyrosine interactome of the ErbB-receptor kinase family. <b>2005</b> , 1, 2005.0008	399

1684	The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. <b>2005</b> , 16, 5832-42	80
1683	Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. <b>2005</b> , 68, 502-10	92
1682	ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. <b>2005</b> , 65, 1858-67	249
1681	Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. <b>2005</b> , 65, 5848-56	39
1680	Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. <b>2005</b> , 97, 1663-70	70
1679	DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. <b>2005</b> , 25, 5040-51	40
1678	Proliferation and polarity in breast cancer: untying the Gordian knot. <b>2005</b> , 4, 646-9	17
1677	Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. <b>2005</b> , 27, 1441	1
1676	Epidermal growth factor-mediated growth control of confluent mammary epithelial cells cultured on artificial basement membrane. <b>2005</b> , 16, 395	
1675	From XenoMouse <sup>®</sup> Technology to Panitumumab (ABX-EGF). <b>2005</b> , 647-657	3
1674	Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. <b>2005</b> , 26, 1177-85	25
1673	Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. <b>2005</b> , 64, 1-9	45
1672	Met activation and receptor dimerization in cancer: a role for the Sema domain. <b>2005</b> , 4, 683-5	31
1671	Who will benefit from treatment against EGFR?. <b>2005</b> , 6, 257-8	12
1670	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. <b>2005</b> , 6, 383-91	170
1669	Novel Experimental Therapeutic Approaches for Prostate Cancer. <b>2005</b> , 3, 227-239	
1668	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <b>2005</b> , 76, 151-6	24
1667	Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. <b>2005</b> , 304, 604-19	136

1666	Ligand depletion negatively controls the mitogenic activity of epidermal growth factor. <b>2005</b> , 304, 630-41	4
1665	A FRET-based probe for epidermal growth factor receptor bound non-covalently to a pair of synthetic amphipathic helices. <b>2005</b> , 307, 142-52	24
1664	Differentiation of a mouse submandibular gland-derived cell line (SCA) grown on matrigel. <b>2005</b> , 308, 394-406	5
1663	Bax activation and translocation to mitochondria mediate EGF-induced programmed cell death. <b>2005</b> , 118, 5681-90	24
1662	Analysis of Ras:RasGEF interactions by phage display and static multi-angle light scattering. <b>2005</b> , 37, 197-202	4
1661	Race, gender and mutations in the prediction of anti-EGFR activity. <b>2005</b> , 1, 201-4	
1660	Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. <b>2005</b> , 7, 921-9	80
1659	Regulator of epidermal growth factor signaling: Sprouty. <b>2006</b> , 327, 61-83	5
1658	Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. <b>2005</b> , 24, 582-94	32
1657	In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. <b>2005</b> , 20, 239-48	75
1656	Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. <b>2005</b> , 280, 10870-6	173
1655	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. <b>2005</b> , 23, 5900-9	1250
1654	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. <b>2005</b> , 9, 1009-30	45
1653	A compendium of signals and responses triggered by prodeath and prosurvival cytokines. <b>2005</b> , 4, 1569-90	116
1652	Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. <b>2005</b> , 5, 101-12	11
1651	Pathway proteomics: global and focused approaches. <b>2005</b> , 5, 113-22	5
1650	Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. <b>2005</b> , 5, 303-15	21
1649	Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. <b>2005</b> , 280, 10025-33	74

1648	Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. <b>2005</b> , 288, G447-56	109
1647	Cell stimulus and lysis in a microfluidic device with segmented gas-liquid flow. <b>2005</b> , 77, 3629-36	74
1646	The distinctive nature of HER2-positive breast cancers. <b>2005</b> , 353, 1652-4	341
1645	Anilindialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. <b>2005</b> , 48, 7445-56	32
1644	Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. <b>2005</b> , 42, 1121-4	31
1643	Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. <b>2005</b> , 94, 23-37	28
1642	Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. <b>2005</b> , 36, 250-61	136
1641	Resumption of oocyte meiosis in mammals: on models, meiosis activating sterols, steroids and EGF-like factors. <b>2005</b> , 234, 37-45	44
1640	The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. <b>2005</b> , 335, 1173-8	28
1639	Resistance to epidermal growth factor receptor-targeted therapy. <b>2005</b> , 8, 298-310	66
1638	ETS transcription factors and their emerging roles in human cancer. <b>2005</b> , 41, 2462-78	340
1637	The role of carbonic anhydrase IX overexpression in kidney cancer. <b>2005</b> , 41, 2935-47	129
1636	Growth factors and their relationship to neoplastic and paraneoplastic disease. <b>2005</b> , 16, 83-94	3
1635	The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. <b>2005</b> , 217, 73-86	46
1634	Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. <b>2005</b> , 224, 117-21	45
1633	Antitumor activity of HER-2 inhibitors. <b>2005</b> , 227, 9-23	77
1632	Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. <b>2005</b> , 226, 37-47	42
1631	Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. <b>2005</b> , 227, 201-12	39

1630	Growth factor receptor signalling in human lens cells: role of the calcium store. <b>2005</b> , 80, 885-95	31
1629	Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. <b>2005</b> , 579, 145-52	68
1628	Heterogeneities in EGF receptor density at the cell surface can lead to concave up scatchard plot of EGF binding. <b>2005</b> , 579, 3043-7	30
1627	Current challenges in quantitative modeling of epidermal growth factor signaling. <b>2005</b> , 579, 6289-94	25
1626	Breast cancer metastasis to the central nervous system. <b>2005</b> , 167, 913-20	327
1625	G-protein-coupled receptor signaling and the EGF network in endocrine systems. <b>2005</b> , 16, 320-6	54
1624	Neuregulin-1 type III determines the ensheathment fate of axons. <b>2005</b> , 47, 681-94	554
1623	[Molecular alterations in breast cancer: clinical implications and new analytical tools]. <b>2005</b> , 26, 470-8	3
1622	Cetuximab in previously treated colorectal cancer. <b>2005</b> , 5 Suppl 1, S28-33	8
1621	Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. <b>2005</b> , 5 Suppl 2, S81-8	7
1620	ADAM proteases, ErbB pathways and cancer. <b>2005</b> , 14, 591-606	20
1619	TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints. <b>2005</b> , 34, 204-11	33
1618	Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. <b>2005</b> , 47, 315-23	29
1617	The role of disulfide bonds in the structure and function of murine epidermal growth factor (mEGF). <b>2005</b> , 23, 97-110	13
1616	Inhibitors of Protein Kinases and Protein Phosphates. <b>2005</b> ,	1
1615	Role of HER2/HER3 co-receptor in breast carcinogenesis. <b>2005</b> , 1, 841-9	31
1614	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. <b>2005</b> , 48, 1107-31	252
1613	A comprehensive pathway map of epidermal growth factor receptor signaling. <b>2005</b> , 1, 2005.0010	730



1612	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. <b>2005</b> , 23, 2556-68	525
1611	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. <b>2005</b> , 45, 357-84	107
1610	Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. <b>2005</b> , 20, 603-13	31
1609	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <b>2005</b> , 353, 1659-72	3921
1608	HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. <b>2005</b> , 7, R1058-79	42
1607	Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. <b>2005</b> , 7, R708-18	33
1606	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. <b>2005</b> , 7, R617-26	75
1605	Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. <b>2005</b> , 7, R204-9	51
1604	Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. <b>2005</b> , 7, R267-73	67
1603	Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. <b>2006</b> , 8, R67	15
1602	Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. <b>2006</b> , 8, R35	25
1601	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. <b>2006</b> , 1-35	
1600	Protein Tyrosine Kinases. <b>2006</b> ,	4
1599	Cancer du sein. <b>2006</b> ,	
1598	Breast Cancer and Molecular Medicine. <b>2006</b> ,	2
1597	Biomarkers in Breast Cancer. <b>2006</b> ,	3
1596	Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. <b>2006</b> , 12, 2591-6	117
1595	Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. <b>2006</b> , 5, 2947-55	32

1594	Cancer Drug Resistance. <b>2006,</b>	17
1593	Multifunctional transcription factor YY1: a therapeutic target in human cancer?. <b>2006, 10,</b> 253-66	32
1592	Optimal treatment of metastatic colorectal cancer. <b>2006, 6,</b> 801-12	15
1591	Epidermal growth factor receptor as a major anticancer drug target. <b>2006, 10,</b> 877-88	6
1590	Recent developments in colorectal cancer treatment by monoclonal antibodies. <b>2006, 6,</b> 1175-92	15
1589	Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. <b>2006, 5,</b> 1494-501	53
1588	Potential use of humanized antibodies in the treatment of breast cancer. <b>2006, 6,</b> 1065-74	14
1587	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. <b>2006, 11,</b> 665-83	1
1586	Cancer therapies targeted to the epidermal growth factor receptor and its family members. <b>2006,</b> 16, 147-164	3
1585	Histone deacetylase inhibitors in cancer therapy. <b>2006, 24,</b> 521-7	40
1584	Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. <b>2006, 316,</b> 255-60	50
1583	Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. <b>2006, 48,</b> 173-9	46
1582	The epidermal growth factor receptor pathway: a model for targeted therapy. <b>2006, 12,</b> 5268-72	649
1581	Developmental dental toxicity of dioxin and related compounds--a review. <b>2006, 56,</b> 323-31	44
1580	Potential of biologically targeted therapies for breast cancer. <b>2006, 4,</b> 23-26	1
1579	Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. <b>2006, 25,</b> 3277-85	7
1578	Contrasting role of phospholipase C-gamma1 in the expression of immediate early genes induced by epidermal or platelet-derived growth factors. <b>2006, 312,</b> 807-16	7
1577	HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. <b>2006, 312,</b> 2791-805	52

1576	Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbix) results in paradox phosphorylation of tyrosine 1173 in the receptor. <b>2006</b> , 580, 4793-800	27
1575	Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. <b>2006</b> , 90, 3993-4009	55
1574	Targeting tyrosine kinases in cancer: the second wave. <b>2006</b> , 312, 1175-8	380
1573	Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. <b>2006</b> , 175, 1127-32	31
1572	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. <b>2006</b> , 66, 1441-63	11
1571	A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. <b>2006</b> , 5, 363-7	26
1570	Vaccination for treatment and prevention of cancer in animal models. <b>2006</b> , 90, 175-213	70
1569	Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells. <b>2006</b> , 169, 823-30	59
1568	Biotin-ligand complexes with streptavidin quantum dots for in vivo cell labeling of membrane receptors. <b>2007</b> , 374, 69-79	22
1567	Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. <b>2006</b> , 60, 132-40	373
1566	Changing the course of oncogenesis: The development of tyrosine kinase inhibitors. <b>2006</b> , 4, 14-20	2
1565	Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. <b>2006</b> , 66, 2173-80	180
1564	ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas. <b>2006</b> , 2, 765-81	32
1563	The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. <b>2006</b> , 94, 1703-9	67
1562	Clinical activity of pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. <b>2006</b> , 24, 4324-32	209
1561	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. <b>2006</b> , 10, 306-15	34
1560	Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases. <b>2006</b> , 580, 1859-64	24
1559	Growth factor receptors in helminth parasites: signalling and host-parasite relationships. <b>2006</b> , 580, 2968-75	46

1558	Cellular conference call: external feedback affects cell-fate decisions. <b>2006</b> , 124, 1128-30	7
1557	An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. <b>2006</b> , 125, 1137-49	1137
1556	EGF receptor activation: push comes to shove. <b>2006</b> , 125, 1029-31	24
1555	SmpKC1, a new protein kinase C identified in the platyhelminth parasite <i>Schistosoma mansoni</i> . <b>2006</b> , 345, 1138-48	17
1554	BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. <b>2006</b> , 348, 406-12	69
1553	Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. <b>2006</b> , 349, 372-82	20
1552	ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains. <b>2006</b> , 350, 629-33	18
1551	Epidermal growth factor receptor (EGFR) signaling in cancer. <b>2006</b> , 366, 2-16	1421
1550	Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors. <b>2006</b> , 60, 629-32	5
1549	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. <b>2006</b> , 237, 89-94	39
1548	KAI1/CD82, a tumor metastasis suppressor. <b>2006</b> , 240, 183-94	102
1547	High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. <b>2006</b> , 239, 292-7	22
1546	Key cancer cell signal transduction pathways as therapeutic targets. <b>2006</b> , 42, 290-4	118
1545	A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. <b>2006</b> , 42, 2425-32	88
1544	Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. <b>2006</b> , 42, 636-45	51
1543	Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. <b>2006</b> , 24, 121-36	111
1542	Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. <b>2006</b> , 43, 667-76	12
1541	"To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function. <b>2006</b> , 41, 215-8	22

1540	Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. <b>2006</b> , 88, 114-22	18
1539	EGFR as a target: rationale for therapy. <b>2006</b> , 22, 5-9	11
1538	Clinical experience with anti-EGFR therapy. <b>2006</b> , 22, 10-9	11
1537	Epidermal growth factor receptor pathway inhibitors. <b>2006</b> , 1, 299-310	5
1536	Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor $\beta$ negative fulvestrant-resistant MCF-7 cells. <b>2006</b> , 29, 1237	4
1535	Antibody Therapy for Solid Tumors. <b>2006</b> , 433-444	
1534	ErbB and HB-EGF signaling in heart development and function. <b>2006</b> , 31, 1-14	97
1533	Biomolecular markers of breast cancer. <b>2006</b> , 11, 1818-43	51
1532	Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. <b>2006</b> , 15, 103-111	12
1531	SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells. <b>2006</b> , 47, 2832-9	42
1530	Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. <b>2006</b> , 15, 673-80	14
1529	Sequential Adjuvant Hormone Therapy in Postmenopausal Breast Cancer: Rationale and Clinical Results. <b>2006</b> , 21, 111-122	
1528	erb-B2 as a Therapeutic Target. <b>2006</b> , 159-175	1
1527	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. <b>2006</b> , 1-29	3
1526	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. <b>2006</b> , 396, 79-88	15
1525	Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. <b>2006</b> , 29, 1003	6
1524	Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. <b>2006</b> , 4, 955-66	14
1523	Natural Killer Cells for the Treatment of Malignancies*. <b>2006</b> , 33, 144-149	5

1522	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. <b>2006</b> , 1, 406-412	20
1521	Autocrine Growth Factor Signaling in Motility. <b>2006</b> , 89-109	1
1520	Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. <b>2006</b> , 29, 269	3
1519	Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. <b>2006</b> , 16, 533	1
1518	A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. <b>2006</b> , 45, 15529-40	44
1517	Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. <b>2006</b> , 65, 1181-8	134
1516	Rational Development of Targeted Cancer Therapies Using Biomarkers. <b>2006</b> , 37, 482-489	
1515	Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. <b>2006</b> , 65, 162-75	41
1514	Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. <b>2006</b> , 65, 769-75	26
1513	In vivo cell imaging with semiconductor quantum dots and noble metal nanodots. <b>2006</b> ,	2
1512	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. <b>2006</b> , 1, 406-412	34
1511	Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. <b>2006</b> , 5, 1361-8	63
1510	Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. <b>2006</b> , 29, 90-5	28
1509	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. <b>2006</b> , 30, 1097-104	206
1508	Canonical WNT signaling pathway and human AREG. <b>2006</b> , 17, 1163	0
1507	Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods. <b>2006</b> , 29, 1159	5
1506	Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. <b>2006</b> , 28, 1531	0
1505	ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. <b>2006</b> , 41, 1205-12	30

1504	Salivary gland branching morphogenesis. <b>2006</b> , 74, 349-64	218
1503	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. <b>2006</b> , 11, 287-91	6
1502	HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. <b>2006</b> , 19, 224-31	46
1501	Interactions between beta-neuregulin and neurotrophins in motor neuron apoptosis. <b>2006</b> , 97, 222-33	34
1500	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. <b>2006</b> , 16 Suppl 1, 152-65	41
1499	Syntaxin 9 is enriched in skin hair follicle epithelium and interacts with the epidermal growth factor receptor. <b>2006</b> , 7, 216-26	11
1498	Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. <b>2006</b> , 7, 686-98	75
1497	Cytomics - importance of multimodal analysis of cell function and proliferation in oncology. <b>2006</b> , 39, 495-505	28
1496	Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. <b>2006</b> , 36, 588-96	58
1495	Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. <b>2006</b> , 97, 341-7	102
1494	AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. <b>2006</b> , 49, 161-9	11
1493	Tyrosine phosphorylation controls PCNA function through protein stability. <b>2006</b> , 8, 1359-68	239
1492	ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. <b>2006</b> , 12, 961-6	103
1491	State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. <b>2006</b> , 3, 825-31	83
1490	Vaccines for tumour prevention. <b>2006</b> , 6, 204-16	256
1489	Comparing antibody and small-molecule therapies for cancer. <b>2006</b> , 6, 714-27	531
1488	Integration of EGFR inhibitors with radiochemotherapy. <b>2006</b> , 6, 876-85	233
1487	Mechanisms of cutaneous toxicities to EGFR inhibitors. <b>2006</b> , 6, 803-12	555

1486	Panitumumab. <b>2006</b> , 5, 987-8		54
1485	Cell-signalling dynamics in time and space. <i>Nature Reviews Molecular Cell Biology</i> , <b>2006</b> , 7, 165-76	48.7	1022
1484	EGF-ERBB signalling: towards the systems level. <i>Nature Reviews Molecular Cell Biology</i> , <b>2006</b> , 7, 505-16	48.7	1572
1483	Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. <b>2006</b> , 94, 85-92		57
1482	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. <b>2006</b> , 19, 1213-20		59
1481	A quantitative protein interaction network for the ErbB receptors using protein microarrays. <b>2006</b> , 439, 168-74		629
1480	Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. <b>2006</b> , 13, 576-85		56
1479	Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. <b>2006</b> , 25, 752-62		94
1478	Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. <b>2006</b> , 25, 3234-44		170
1477	p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. <b>2006</b> , 25, 4195-206		158
1476	The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase. <b>2006</b> , 25, 160-3		49
1475	Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. <b>2006</b> , 25, 2452-67		125
1474	Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. <b>2006</b> , 25, 3286-95		81
1473	Transforming growth factor alpha acts as a gliatrophin for mouse and human astrocytes. <b>2006</b> , 25, 4076-85		24
1472	Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation. <b>2006</b> , 25, 5495-506		34
1471	Comparative and integrative functional genomics of HCC. <b>2006</b> , 25, 3801-9		96
1470	Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. <b>2006</b> , 25, 6457-66		27
1469	Gab1 signaling is regulated by EGF receptor sorting in early endosomes. <b>2006</b> , 25, 6604-17		13



1468	Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. <b>2006</b> , 25, 7267-73	40
1467	Epidermal growth factor receptor expression and activation in neuroendocrine tumours. <b>2006</b> , 18, 355-60	76
1466	Epidermal growth factor receptor directed therapy in head and neck cancer. <b>2006</b> , 57, 25-43	44
1465	Cetuximab in advanced non-small cell lung cancer. <b>2006</b> , 59, 139-49	16
1464	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. <b>2006</b> , 16, 1633-7	37
1463	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. <b>2006</b> , 16, 1969-74	64
1462	5-benzylidene-hydantoin s as new EGFR inhibitors with antiproliferative activity. <b>2006</b> , 16, 4021-5	64
1461	Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. <b>2006</b> , 64, 551-61	28
1460	Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. <b>2006</b> , 66, 500-4	50
1459	Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin"). <b>2006</b> , 66, 528-36	26
1458	Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. <b>2006</b> , 28, 159-68	46
1457	Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. <b>2006</b> , 58, 723-34	58
1456	Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. <b>2006</b> , 23, 1275-84	81
1455	ErbB receptor negative regulatory mechanisms: implications in cancer. <b>2006</b> , 11, 89-99	16
1454	Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. <b>2006</b> , 97, 49-55	17
1453	ADAMs, cell migration and cancer. <b>2006</b> , 25, 57-68	100
1452	Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells. <b>2006</b> , 285, 165-71	7
1451	Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. <b>2006</b> , 77, 33-45	16

1450	Localization of thymosin beta10 in breast cancer cells: relationship to actin cytoskeletal remodeling and cell motility. <b>2007</b> , 127, 109-13	17
1449	Trastuzumab and breast cancer: developments and current status. <b>2006</b> , 11, 199-208	109
1448	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. <b>2006</b> , 33, 631-8	58
1447	Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR. <b>2006</b> , 55, 386-93	4
1446	Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. <b>2006</b> , 55, 717-27	244
1445	Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. <b>2006</b> , 55, 1091-9	16
1444	Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. <b>2007</b> , 59, 235-49	23
1443	Nano-oncology: drug delivery, imaging, and sensing. <b>2006</b> , 384, 620-30	363
1442	Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors. <b>2006</b> , 16, 2419-22	19
1441	Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. <b>2006</b> , 104, 146-55	66
1440	Mediterranean diet, olive oil and cancer. <b>2006</b> , 8, 15-21	80
1439	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <b>2006</b> , 1, 23-33	1
1438	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. <b>2006</b> , 1, 123-129	3
1437	Multimodality treatment of esophageal cancer: a review of the current status and future directions. <b>2006</b> , 8, 174-82	14
1436	HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. <b>2006</b> , 10, 25-38	376
1435	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. <b>2006</b> , 10, 39-50	311
1434	Targeting ADAMS and ERBBs in lung cancer. <b>2006</b> , 10, 7-11	33
1433	The complexity of targeting EGFR signalling in cancer: from expression to turnover. <b>2006</b> , 1766, 120-39	106

1432	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. <b>2006</b> , 1766, 217-29	27
1431	Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. <b>2006</b> , 71, 751-60	33
1430	Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. <b>2006</b> , 71, 1422-34	68
1429	The phyto-chemical (-)-epigallocatechin gallate suppresses gene expression of epidermal growth factor receptor in rat hepatic stellate cells in vitro by reducing the activity of Egr-1. <b>2006</b> , 72, 227-38	21
1428	A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. <b>2006</b> , 15, 728-35	14
1427	New therapies in the treatment of breast cancer. <b>2006</b> , 33, S3-8	14
1426	Epidermal growth factor receptor targeting in cancer. <b>2006</b> , 33, 369-85	560
1425	Protein-protein interactions in the allosteric regulation of protein kinases. <b>2006</b> , 16, 702-9	89
1424	Molecular correlates of site-specific metastasis. <b>2006</b> , 16, 102-10	20
1423	Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. <b>2006</b> , 14, 401-14	48
1422	Emerging roles of pseudokinases. <b>2006</b> , 16, 443-52	414
1421	ErbB receptors: new insights on mechanisms and biology. <b>2006</b> , 16, 649-56	266
1420	Human cytomegalovirus-induced inhibition of cytotrophoblast invasion in a first trimester extravillous cytotrophoblast cell line. <b>2006</b> , 27, 137-47	40
1419	Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. <b>2006</b> , 7, 250-6	68
1418	A fluid membrane-based soluble ligand-display system for live-cell assays. <b>2006</b> , 7, 436-40	34
1417	Development of antibody-based therapeutics for oncology indications. <b>2006</b> , 67, 699-728	2
1416	Regulation of early <i>Xenopus</i> development by ErbB signaling. <b>2006</b> , 235, 301-14	13
1415	ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. <b>2006</b> , 206, 702-8	36

1414	Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. <b>2006</b> , 209, 645-52	106
1413	Genetic alterations in urothelial bladder carcinoma: an updated review. <b>2006</b> , 106, 1205-16	58
1412	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. <b>2006</b> , 107, 1207-18	153
1411	Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. <b>2006</b> , 44, 1012-24	284
1410	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. <b>2006</b> , 118, 209-14	130
1409	EGFR and erbB2 mutation status in Japanese lung cancer patients. <b>2006</b> , 118, 180-4	146
1408	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <b>2006</b> , 118, 1041-50	33
1407	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. <b>2006</b> , 119, 727-34	16
1406	MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. <b>2006</b> , 119, 8-16	61
1405	EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. <b>2006</b> , 119, 1236-48	57
1404	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. <b>2006</b> , 26, 569-94	101
1403	Overexpression of ErbB2 and ErbB3 receptors in Schwann cells of patients with Charcot-Marie-tooth disease type 1A. <b>2006</b> , 33, 342-9	15
1402	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. <b>2006</b> , 45, 288-301	25
1401	Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation. <b>2006</b> , 45, 204-12	25
1400	Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. <b>2006</b> , 2, 54	188
1399	New tools for dissecting RON receptor tyrosine kinase oncogenic signaling. <b>2006</b> , 5, 1187-8	
1398	Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. <b>2006</b> , 18, 497	0
1397	Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. <b>2006</b> , 70, 161-7	22

1396	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. <b>2006</b> , 66, 3197-204	229
1395	Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. <b>2006</b> , 66, 6243-9	104
1394	Activation of the lutropin/choriogonadotropin receptor in MA-10 cells stimulates tyrosine kinase cascades that activate ras and the extracellular signal regulated kinases (ERK1/2). <b>2006</b> , 147, 3419-27	35
1393	A delayed gonadotropin-dependent and growth factor-mediated activation of the extracellular signal-regulated kinase 1/2 cascade negatively regulates aromatase expression in granulosa cells. <b>2006</b> , 20, 3308-20	51
1392	Role of the epidermal growth factor network in ovarian follicles. <b>2006</b> , 20, 715-23	267
1391	Serum HER-2 concentration in patients with primary breast cancer. <b>2006</b> , 59, 373-6	26
1390	Neuregulin-dependent protein synthesis in C2C12 myotubes and rat diaphragm muscle. <b>2006</b> , 291, C1056-61	29
1389	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. <b>2006</b> , 12, 4436s-4440s	29
1388	Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. <b>2006</b> , 177, 7626-33	69
1387	Neuregulins. <b>2006</b> , 1401-1406	
1386	Signal processing in the TGF-beta superfamily ligand-receptor network. <b>2006</b> , 2, e3	100
1385	Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. <b>2006</b> , 66, 5201-8	47
1384	Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). <b>2006</b> , 7, 495-502	72
1383	Role of a tyrosine kinase in the CO <sub>2</sub> -induced stimulation of HCO <sub>3</sub> <sup>-</sup> reabsorption by rabbit S2 proximal tubules. <b>2006</b> , 291, F358-67	24
1382	The epidermal growth factor family has a dual role in deciding the fate of cancer cells. <b>2006</b> , 66, 623-30	10
1381	ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. <b>2006</b> , 66, 3715-25	57
1380	Lapatinib: current status and future directions in breast cancer. <b>2006</b> , 11, 1047-57	120
1379	Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. <b>2006</b> , 26, 6283-98	187

1378	ErbB receptor regulation by dexamethasone in mouse type II epithelial cells. <b>2006</b> , 28, 1117-23	14
1377	Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. <b>2006</b> , 13, 39-49	89
1376	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. <b>2006</b> , 12, 7406-13	17
1375	Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. <b>2006</b> , 12, 6161-9	15
1374	Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. <b>2006</b> , 26, 831-42	77
1373	ErbB3-dependent motility and intravasation in breast cancer metastasis. <b>2006</b> , 66, 1418-26	78
1372	Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. <b>2006</b> , 24, 3735-46	62
1371	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. <b>2007</b> , 44, 166-72	37
1370	Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. <b>2006</b> , 4, 983-98	28
1369	Src homology 2 domain-based high throughput assays for profiling downstream molecules in receptor tyrosine kinase pathways. <b>2006</b> , 5, 959-68	10
1368	Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. <b>2006</b> , 11, 857-67	73
1367	ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. <b>2006</b> , 12, 1008s-1012s	37
1366	A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. <b>2006</b> , 80, 5531-9	41
1365	Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. <b>2006</b> , 20, 939-53	44
1364	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. <b>2006</b> , 12, 4671-7	56
1363	Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. <b>2006</b> , 17, 67-79	114
1362	Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. <b>2006</b> , 319, 1070-80	89
1361	The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. <b>2006</b> , 66, 6412-20	171

1360	Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. <b>2006</b> , 66, 11279-86	70
1359	erbB2 is required for G protein-coupled receptor signaling in the heart. <b>2006</b> , 103, 15889-93	45
1358	Drugs Affecting Growth of Tumours. <b>2006</b> ,	1
1357	A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. <b>2006</b> , 12, 5129-35	39
1356	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). <b>2006</b> , 5, 1610-27	72
1355	Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. <b>2006</b> , 66, 10553-9	116
1354	Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. <b>2006</b> , 26, 6412-24	35
1353	Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. <b>2006</b> , 66, 3764-72	96
1352	Novel combinations based on epidermal growth factor receptor inhibition. <b>2006</b> , 12, 4446s-4450s	33
1351	Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. <b>2006</b> , 66, 7734-40	71
1350	Handbook of Metastatic Breast Cancer. <b>2006</b> ,	15
1349	Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. <b>2006</b> , 5, 657-64	139
1348	Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. <b>2006</b> , 319, 1459-66	24
1347	Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice. <b>2006</b> , 66, 6955-63	93
1346	Molecular diagnostics as a tool to personalize treatment in adult glioma patients. <b>2006</b> , 5, 215-29	14
1345	Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?. <b>2006</b> , 24, 3722-5	18
1344	Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. <b>2006</b> , 119, 85-95	59
1343	SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu. <b>2006</b> , 66, 5847-57	8

1342	Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. <b>2006</b> , 66, 867-74	130
1341	A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. <b>2006</b> , 66, 2732-9	59
1340	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. <b>2006</b> , 66, 3802-12	51
1339	Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. <b>2006</b> , 26, 5086-95	96
1338	A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. <b>2006</b> , 45, 1466-76	34
1337	Selection and characterization of Her2 binding-designed ankyrin repeat proteins. <b>2006</b> , 281, 35167-75	77
1336	The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. <b>2006</b> , 281, 19310-9	71
1335	Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. <b>2006</b> , 34, 420-6	176
1334	Novel function of ovarian growth factors: combined studies by DNA microarray, biochemical and physiological approaches. <b>2006</b> , 12, 413-9	27
1333	Is the Vasculature a Potential Therapeutic Target in Arthritis?. <b>2006</b> , 2, 151-158	1
1332	Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. <b>2006</b> , 176, 7695-703	19
1331	Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. <b>2006</b> , 66, 1640-7	123
1330	HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. <b>2006</b> , 66, 9591-600	93
1329	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. <b>2006</b> , 103, 6901-6	122
1328	Formal Executable Models of Cell Signaling Primitives. <b>2006</b> ,	4
1327	Quantum Dots. <b>2006</b> ,	
1326	The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. <b>2006</b> , 25, 246-51	11
1325	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. <b>2006</b> , 66, 1630-9	743



1324	Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?. <b>2006</b> , 103, 17073-4	51
1323	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. <b>2006</b> , 12, 4103-11	209
1322	Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. <b>2006</b> , 24, 4309-16	118
1321	Expression and nuclear localization of ErbB3 in prostate cancer. <b>2006</b> , 12, 2730-7	99
1320	Phosphoproteomic analysis of Her2/neu signaling and inhibition. <b>2006</b> , 103, 9773-8	175
1319	rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. <b>2006</b> , 281, 1099-106	115
1318	The N-terminal domains of neuregulin 1 confer signal attenuation. <b>2006</b> , 281, 27306-16	18
1317	Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands. <b>2006</b> , 281, 40033-40	5
1316	The role of neuregulin-ErbB4 interactions on the proliferation and organization of cells in the subventricular zone. <b>2006</b> , 103, 1930-5	135
1315	Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. <b>2006</b> , 66, 7245-52	97
1314	Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. <b>2006</b> , 66, 7991-8	118
1313	Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. <b>2006</b> , 26, 3378-89	38
1312	131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. <b>2006</b> , 21, 5-14	30
1311	Cetuximab in the treatment of head and neck cancer. <b>2006</b> , 6, 1539-52	23
1310	Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. <b>2006</b> , 66, 6129-38	106
1309	Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. <b>2006</b> , 20, 311-3	40
1308	Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. <b>2006</b> , 66, 6990-7	74
1307	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. <b>2006</b> , 11, 602-11	27

1306	Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer. <b>2006</b> , 70, 1802-11	27
1305	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. <b>2006</b> , 24, 1612-9	181
1304	Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. <b>2007</b> , 3, 144	182
1303	Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. <b>2007</b> , 48, 1562-70	26
1302	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <b>2007</b> , 12, 325-30	54
1301	Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. <b>2007</b> , 25, 5777-84	177
1300	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <b>2007</b> , 7, 821-36	9
1299	Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway. <b>2007</b> , 282, 12698-706	37
1298	In vivo selection for metastasis promoting genes in the mouse. <b>2007</b> , 104, 6696-701	66
1297	Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. <b>2007</b> , 72, 248-58	62
1296	The EGF receptor is required for efficient liver regeneration. <b>2007</b> , 104, 17081-6	224
1295	The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. <b>2007</b> , 67, 1935-42	42
1294	Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart. <b>2007</b> , 71, 1494-502	17
1293	Mapping ErbB receptors on breast cancer cell membranes during signal transduction. <b>2007</b> , 120, 2763-73	83
1292	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. <b>2007</b> , 13, 6175-81	78
1291	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. <b>2007</b> , 97, 1469-74	64
1290	HER family inhibitors in pancreatic cancer: current status and future directions. <b>2007</b> , 11, 337-47	5
1289	Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. <b>2007</b> , 97, 494-501	62

1288	Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. <b>2007</b> , 11, 771-82	4
1287	Isolation and characterization of the Drosophila ubiquitin ortholog dUbqln: in vivo interaction with early-onset Alzheimer disease genes. <b>2007</b> , 16, 2626-39	42
1286	Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. <b>2007</b> , 20, 189-99	88
1285	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. <b>2007</b> , 13, 3368-3377	59
1284	A network analysis of changes in molecular interactions in cellular signaling. <b>2007</b> , 6, 503-13	12
1283	Lapatinib in breast cancer. <b>2007</b> , 18 Suppl 6, vi26-30	60
1282	Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. <b>2007</b> , 13, 3301-4	11
1281	Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. <b>2007</b> , 3, e4	84
1280	Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. <b>2007</b> , 18, 305-10	50
1279	Peritoneal Carcinomatosis. <b>2007</b> ,	3
1278	Targeted therapies for non-small cell lung cancer. <b>2007</b> , 13, 2810-31	13
1277	ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells. <b>2007</b> , 293, L429-35	25
1276	Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. <b>2007</b> , 46, 951-60	13
1275	Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. <b>2007</b> , 46, 1113-7	30
1274	Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. <b>2007</b> , 25, 2656-63	51
1273	Cancer du sein. <b>2007</b> ,	2
1272	Erlotinib in non-small cell lung cancer treatment: current status and future development. <b>2007</b> , 12, 840-9	90
1271	Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. <b>2007</b> , 7, 191-201	50

1270	Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. <b>2007</b> , 16, 154-64	17
1269	Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis. <b>2007</b> , 2007, re3	14
1268	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. <b>2007</b> , 6, 93-100	51
1267	Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. <b>2007</b> , 6, 2664-74	41
1266	EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. <b>2007</b> , 6, 571-9	8
1265	Spectral Decomposition of Signaling Networks. <b>2007</b> ,	1
1264	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. <b>2007</b> , 2, 335-48	3
1263	Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. <b>2007</b> , 81, 6241-7	90
1262	The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. <b>2007</b> , 21, 1861-76	29
1261	Emerging drugs for targeted therapy of bladder cancer. <b>2007</b> , 12, 435-48	5
1260	EGF receptor activation decreases retroviral gene transfer through protein kinase C-delta. <b>2007</b> , 15, 369-77	5
1259	Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. <b>2007</b> , 78, 1-22	60
1258	Erlotinib in cancer treatment. <b>2007</b> , 18 Suppl 6, vi35-41	72
1257	Panitumumab a novel drug in cancer treatment. <b>2007</b> , 18 Suppl 6, vi16-21	24
1256	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. <b>2007</b> , 99, 694-705	160
1255	Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. <b>2007</b> , 26, 178-85	17
1254	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <b>2007</b> , 7, 257-68	84
1253	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. <b>2007</b> , 959-992	2

1252	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. <b>2007</b> , 13, 4909-19	406
1251	ErbB-dependent signaling as a determinant of trastuzumab resistance. <b>2007</b> , 13, 4657-9	18
1250	Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. <b>2007</b> , 67, 5293-9	67
1249	Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. <b>2007</b> , 67, 3406-11	37
1248	Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. <b>2007</b> , 18, 176-88	253
1247	Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. <b>2007</b> , 104, 5860-5	444
1246	Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. <b>2007</b> , 6, 150-69	32
1245	Oxaliplatin in the treatment of colorectal cancer. <b>2007</b> , 3, 281-94	18
1244	A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. <b>2007</b> , 13, 7506-14	24
1243	Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. <b>2007</b> , 67, 3794-800	48
1242	Combinatorial RNAi for quantitative protein network analysis. <b>2007</b> , 104, 6579-84	52
1241	Biology of interactions: anti-epidermal growth factor receptor agents. <b>2007</b> , 25, 4057-65	184
1240	CETUXIMAB (ERBITUX <sup>®</sup> ), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. <b>2007</b> , 43-67	
1239	UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. <b>2007</b> , 282, 1658-69	113
1238	EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. <b>2007</b> , 16, 1639-47	72
1237	Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. <b>2007</b> , 13, 6579-84	128
1236	WWOX expression in different histologic types and subtypes of non-small cell lung cancer. <b>2007</b> , 13, 884-91	51
1235	EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. <b>2007</b> , 120, 3688-99	77

1234	Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. <b>2007</b> , 25, 675-81	84
1233	Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. <b>2007</b> , 178, 1021-9	21
1232	Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. <b>2007</b> , 25, 4423-30	59
1231	ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. <b>2007</b> , 18, 4446-56	38
1230	Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. <b>2007</b> , 282, 1479-86	494
1229	Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. <b>2007</b> , 81, 5705-13	19
1228	Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. <b>2007</b> , 67, 7256-65	52
1227	Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. <b>2007</b> , 67, 9887-93	46
1226	Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. <b>2007</b> , 67, 1228-38	67
1225	Breast Cancer. <b>2007</b> ,	
1224	Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. <b>2007</b> , 13, 1405-11	96
1223	Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. <b>2007</b> , 67, 8716-24	25
1222	Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. <b>2007</b> , 5, 393-401	8
1221	Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. <b>2007</b> , 67, 4164-72	67
1220	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. <b>2007</b> , 3, 242-248	
1219	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <b>2007</b> , 3, 276-283	
1218	Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside. <b>2007</b> , 3, 159-167	
1217	Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells. <b>2007</b> , 120, 4289-301	40

1216	Luteinizing hormone-dependent activation of the epidermal growth factor network is essential for ovulation. <b>2007</b> , 27, 1914-24	273
1215	Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. <b>2007</b> , 67, 7579-88	23
1214	Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. <b>2007</b> , 13, 1892-902	114
1213	Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer. <b>2007</b> , 13, 3147-55	21
1212	Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. <b>2007</b> , 6, 1629-40	84
1211	Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <b>2007</b> , 72, 388-96	15
1210	p120 catenin regulates lamellipodial dynamics and cell adhesion in cooperation with cortactin. <b>2007</b> , 104, 10882-7	74
1209	Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase. <b>2007</b> , 282, 19399-409	58
1208	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <b>2007</b> , 18, 421-30	36
1207	Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. <b>2007</b> , 103, 56-66	40
1206	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. <b>2007</b> , 3, 151	115
1205	EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. <b>2007</b> , 17, 1405	
1204	Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. <b>2007</b> , 31, 1223	
1203	UV light blocks EGFR signalling in human cancer cell lines. <b>2007</b> , 30, 181-5	5
1202	A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. <b>2007</b> , 15, 94-102	47
1201	Biological applications of an LCoS-based programmable array microscope (PAM). <b>2007</b> ,	10
1200	Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. <b>2007</b> , 30, 254-60	26
1199	Chemotherapy. 97-109	0

1198	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <b>2007</b> , 17, 313-9	49
1197	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. <b>2007</b> , 19, 56-62	76
1196	Epidermal growth factor stimulates chloride transport in primary cultures of weanling and adult rabbit colonocytes. <b>2007</b> , 44, 300-11	6
1195	Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. <b>2007</b> , 26, 235-41	21
1194	Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. <b>2007</b> , 2, 111-6	39
1193	The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. <b>2007</b> , 17, 887-93	16
1192	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <b>2007</b> ,	9
1191	Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens—evidence of schedule-dependent synergy. <b>2007</b> , 69, 390-4	47
1190	Regulation of <i>Xenopus</i> gastrulation by ErbB signaling. <b>2007</b> , 303, 93-107	19
1189	Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer. <b>2007</b> , 307, 340-55	86
1188	The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. <b>2007</b> , 54, 583-97	285
1187	Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. <b>2007</b> , 149, 861-70	68
1186	Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. <b>2007</b> , 34, 55-70	62
1185	Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. <b>2007</b> , 34, 609-18	71
1184	Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. <b>2007</b> , 608, 119-29	96
1183	Heregulinbeta activates store-operated Ca <sup>2+</sup> channels through c-erbB2 receptor level-dependent pathway in human breast cancer cells. <b>2007</b> , 458, 244-52	6
1182	Caspases and receptor cleavage. <b>2007</b> , 462, 162-70	25
1181	Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). <b>2007</b> , 43, 481-9	121



1180	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). <b>2007</b> , 43, 725-35	38
1179	Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. <b>2007</b> , 43, 1117-24	71
1178	EGFR gene and protein expression in breast cancers. <b>2007</b> , 33, 956-60	32
1177	Ganglioside GM(3) is stably associated to tyrosine-phosphorylated ErbB2/EGFR receptor complexes and EGFR monomers, but not to ErbB2. <b>2007</b> , 1771, 873-8	6
1176	Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. <b>2007</b> , 354, 154-9	81
1175	Breast cancer: the upgraded role of HER-3 and HER-4. <b>2007</b> , 39, 851-6	49
1174	Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. <b>2007</b> , 39, 857-62	21
1173	Molecular targeted therapies in breast cancer: where are we now?. <b>2007</b> , 39, 1375-87	29
1172	Rational bases for the development of EGFR inhibitors for cancer treatment. <b>2007</b> , 39, 1416-31	95
1171	Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. <b>2007</b> , 39, 2173-82	45
1170	Expression of single-chain antibody-barstar fusion in plants. <b>2007</b> , 89, 31-8	29
1169	Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. <b>2007</b> , 248, 32-40	26
1168	Amphiregulin: a new growth factor in hepatocarcinogenesis. <b>2007</b> , 254, 30-41	68
1167	Potential Leydig cell mitogenic signals generated by the wild-type and constitutively active mutants of the lutropin/choriogonadotropin receptor (LHR). <b>2007</b> , 260-262, 244-8	19
1166	Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. <b>2007</b> , 56, 460-5	42
1165	Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. <b>2007</b> , 38, 1184-91	45
1164	Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. <b>2007</b> , 581, 41-4	85
1163	The potential role of the EGFR/ERBB2 heterodimer in breast cancer. <b>2007</b> , 17, 607-616	6

1162	Kinase Inhibitors for Cancer. <b>2007</b> , 183-220	1
1161	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. <b>2007</b> , 104, 13092-7	203
1160	Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology. <b>2007</b> , 5, 427-429	
1159	EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. <b>2007</b> , 9, 614-24	37
1158	Apoptosis, Senescence, and Cancer. <b>2007</b> ,	6
1157	Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. <b>2007</b> , 9, 111	18
1156	Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. <b>2007</b> , 9, 211	31
1155	HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. <b>2007</b> , 9,	38
1154	Monoclonal Antibody Drug Conjugates for Cancer Therapy. <b>2007</b> , 507-524	1
1153	Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. <b>2007</b> , 7, 147-57	13
1152	Breast Cancer Chemosensitivity. <b>2007</b> ,	2
1151	Molecular pathogenesis of adult brain tumors and the role of stem cells. <b>2007</b> , 25, 891-924, vii	30
1150	Biologics in General Medicine. <b>2007</b> ,	1
1149	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <b>2007</b> , 67, 2643-8	708
1148	Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. <b>2007</b> , 12, 201-10	69
1147	Quantitative and Probabilistic Modeling in Pathway Logic. <b>2007</b> ,	4
1146	The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. <b>2007</b> , 25, 329-33	3
1145	European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006. <b>2007</b> , 7, 269-78	

1144	Epidermal growth factor receptor-targeted therapy for pancreatic cancer. <b>2007</b> , 25, 647-57	23
1143	System properties of ErbB receptor signaling for the understanding of cancer progression. <b>2007</b> , 3, 111-6	4
1142	Panitumumab in colorectal cancer. <b>2007</b> , 7, 967-73	6
1141	Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. <b>2007</b> , 55, 5030-7	63
1140	Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. <b>2007</b> , 67, 2938-43	178
1139	Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding. <b>2007</b> , 46, 4589-97	74
1138	Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. <b>2007</b> , 12, 610-21	277
1137	Chapter 25 Systems Biology and Kinase Signaling. <b>2007</b> , 393-627	2
1136	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. <b>2007</b> , 18, 977-84	406
1135	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. <b>2007</b> , 50, 4027-37	55
1134	Keratinocyte growth factor receptors. <b>2007</b> , 25, 477-85, vii	35
1133	HER2-positive advanced breast cancer. <b>2007</b> , 21, 293-302	6
1132	Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. <b>2007</b> , 55, 349-55	47
1131	PI3K and Erk MAPK mediate ErbB signaling in Xenopus gastrulation. <b>2007</b> , 124, 657-67	18
1130	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. <b>2007</b> , 5, 203-20	323
1129	Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. <b>2007</b> , 3, 31	96
1128	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. <b>2007</b> , 67, 2045-75	97
1127	Trastuzumab--mechanism of action and use in clinical practice. <b>2007</b> , 357, 39-51	1790

1126	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <b>2007</b> , 7, 555-68	106
1125	Erlotinib in non-small-cell lung cancer. <b>2007</b> , 8, 2579-92	10
1124	A dimerization hierarchy in the transmembrane domains of the HER receptor family. <b>2007</b> , 46, 2010-9	63
1123	Protein kinases as targets for cancer treatment. <b>2007</b> , 8, 1005-16	60
1122	Gefitinib Cytotoxicity in Non-small Cell Lung Cancer Cells is Enhanced by Low Dose Cisplatin Due to Ligand-independent EGFR Autophosphorylation. <b>2007</b> , 19, 155-164	
1121	The Rationale for the Combination of Selective EGFR Inhibitors with Cytotoxic Drugs and Radiotherapy. <b>2007</b> , 22, 47-52	10
1120	Role of ubiquitination in IGF-1 receptor signaling and degradation. <b>2007</b> , 2, e340	56
1119	HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. <b>2007</b> , 2, e1138	116
1118	EGFR activation and ultraviolet light-induced skin carcinogenesis. <b>2007</b> , 2007, 97939	20
1117	Targeted Therapeutics in Cancer Treatment. <b>2007</b> , 117-148	
1116	Promising agents at the interface of biology and oncology derived through chemical synthesis. <b>2007</b> , 79, 2189-2216	13
1115	Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. <b>2007</b> , 48, 2242-8	74
1114	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. <b>2007</b> ,	
1113	Evolutionarily conserved structural and functional roles of the FYVE domain. <b>2007</b> , 74, 95-105	21
1112	ErbB receptors: from oncogenes to targeted cancer therapies. <b>2007</b> , 117, 2051-8	396
1111	EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB. <b>2007</b> , 155-178	
1110	Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. <b>2007</b> , 29, 558-65	70
1109	Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. <b>2007</b> , 120, 1874-82	116

1108	Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel. <b>2007</b> , 121, 407-15	34
1107	Overexpression of ErbB2 in the exocrine pancreas induces an inflammatory response but not increased proliferation. <b>2007</b> , 121, 1410-6	11
1106	Signal peptide of eosinophil cationic protein upregulates transforming growth factor-alpha expression in human cells. <b>2007</b> , 100, 1266-75	15
1105	Defining ETS transcription regulatory networks and their contribution to breast cancer progression. <b>2007</b> , 102, 549-59	39
1104	EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. <b>2007</b> , 212, 489-97	111
1103	Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. <b>2007</b> , 110, 980-8	178
1102	Pathogenesis of medulloblastoma and current treatment outlook. <b>2007</b> , 27, 869-90	17
1101	Nerve regeneration along bioengineered scaffolds. <b>2007</b> , 27, 429-38	28
1100	The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer. <b>2007</b> , 17, 3081-6	25
1099	The role of reaction engineering in cancer biology: Bio-imaging informatics reveals implications of the plasma membrane heterogeneities. <b>2007</b> , 62, 5222-5231	
1098	Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. <b>2007</b> , 67, 405-9	102
1097	Neuregulin3 alters cell fate in the epidermis and mammary gland. <b>2007</b> , 7, 105	34
1096	relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. <b>2007</b> , 4, 14	20
1095	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. <b>2007</b> , 49, 352-7	12
1094	Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. <b>2007</b> , 1, 1651-9	51
1093	A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. <b>2007</b> , 26, 462-6	38
1092	Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. <b>2007</b> , 26, 3431-9	62
1091	c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. <b>2007</b> , 26, 3503-10	82

1090	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. <b>2007</b> , 26, 3654-60	116
1089	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. <b>2007</b> , 26, 6469-87	633
1088	Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. <b>2007</b> , 26, 6905-14	56
1087	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. <b>2007</b> , 26, 6968-78	114
1086	From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. <b>2007</b> , 25, 1134-43	165
1085	A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. <b>2007</b> , 9, 961-9	153
1084	Activation of EGFR and ERK by rhomboid signaling regulates the consolidation and maintenance of sleep in <i>Drosophila</i> . <b>2007</b> , 10, 1160-7	192
1083	Are oncoantigens suitable targets for anti-tumour therapy?. <b>2007</b> , 7, 707-13	50
1082	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. <b>2007</b> , 7, 763-77	1887
1081	Modulation of porcine wound repair with a transfected ErbB3 gene and relevant EGF-like ligands. <b>2007</b> , 127, 1030-41	19
1080	The dumb ErbB receptor helps healing. <b>2007</b> , 127, 995-7	1
1079	Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population. <b>2007</b> , 12, 94-104	102
1078	Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity. <b>2007</b> , 96, 284-9	6
1077	A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. <b>2007</b> , 96, 793-800	63
1076	Requirement for ErbB2/ErbB signaling in developing cartilage and bone. <b>2007</b> , 49, 503-13	26
1075	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <b>2007</b> , 75, 788-99	65
1074	The epidermal growth factor receptor: from development to tumorigenesis. <b>2007</b> , 75, 770-87	246
1073	Proliferative responses to growth factors decline rapidly during postnatal maturation of mammalian hair cell epithelia. <b>2007</b> , 25, 1363-72	43

1072	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. <b>2007</b> , 100, 303-9	28
1071	Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. <b>2007</b> , 98, 1498-503	74
1070	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. <b>2007</b> , 98, 1817-24	469
1069	The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. <b>2007</b> , 17, 798-807	57
1068	The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations. <b>2007</b> , 274, 5505-17	14
1067	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. <b>2007</b> , 28, 1476-93	38
1066	The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. <b>2007</b> , 5, 264-70	24
1065	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. <b>2007</b> , 7, 153	269
1064	Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. <b>2007</b> , 7, 199	35
1063	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. <b>2007</b> , 7, 80	132
1062	EGFR associated expression profiles vary with breast tumor subtype. <b>2007</b> , 8, 258	208
1061	Regulation of MAPKs by growth factors and receptor tyrosine kinases. <b>2007</b> , 1773, 1161-76	308
1060	Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholytaurine-induced proliferation of a human colon cancer cell line. <b>2007</b> , 73, 1001-12	66
1059	Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. <b>2007</b> , 1139, 95-109	57
1058	No association between dinucleotide repeat polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer. <b>2007</b> , 172, 29-32	7
1057	EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. <b>2007</b> , 173, 107-13	76
1056	Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. <b>2007</b> , 11, 217-27	779
1055	Mechanisms for oncogenic activation of the epidermal growth factor receptor. <b>2007</b> , 19, 2013-23	216

1054	Malfunctions within the Cbl interactome uncouple receptor tyrosine kinases from destructive transport. <b>2007</b> , 86, 505-12	29
1053	Identification of a novel EGF-sensitive cell cycle checkpoint. <b>2007</b> , 313, 511-26	15
1052	Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. <b>2007</b> , 313, 1588-601	58
1051	Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. <b>2007</b> , 43, 729-34	47
1050	Targeted agents and esophageal cancer--the next step?. <b>2007</b> , 17, 62-9	21
1049	Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. <b>2007</b> , 319, 53-63	40
1048	Future strategies for targeted therapies and tailored patient management in pancreatic cancer. <b>2007</b> , 34, 354-64	8
1047	2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. <b>2007</b> , 7, 660-669	
1046	Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. <b>2007</b> , 25, 1241-51	240
1045	Perspective of trastuzumab treatment. <b>2007</b> , 14, 150-5	7
1044	Targeting EGFR in bladder cancer. <b>2007</b> , 25, 573-9	36
1043	Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. <b>2007</b> , 183, 256-64	62
1042	<sup>99m</sup> Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. <b>2007</b> , 34, 1843-53	69
1041	Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. <b>2007</b> , 56, 303-317	265
1040	Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. <b>2007</b> , 59, 651-9	18
1039	[Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. <b>2007</b> , 28, 261-8	1
1038	Role of heregulin in human cancer. <b>2007</b> , 64, 2358-77	69
1037	EGFR-targeted therapies in colorectal cancer. <b>2007</b> , 50, 1259-70	24



1036	A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations. <b>2007</b> , 35, 1012-25	28
1035	Interaktionen von EGFR- und VEGFR-Inhibitoren mit Chirurgie und Strahlentherapie. <b>2007</b> , 13, 67-72	1
1034	Current status of signal transduction modulators in the treatment of gynecologic malignancies. <b>2007</b> , 8, 383-92	5
1033	Molecular and cellular mechanisms of anthracycline cardiotoxicity. <b>2007</b> , 7, 114-21	118
1032	Advances in image correlation spectroscopy: measuring number densities, aggregation states, and dynamics of fluorescently labeled macromolecules in cells. <b>2007</b> , 49, 141-64	224
1031	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. <b>2007</b> , 9, 543-4	1
1030	Molekulare Mechanismen der Kardiotoxizität von Tyrosinkinaseinhibitoren. <b>2007</b> , 1, 209-216	
1029	Targeted therapies in head and neck cancer. <b>2007</b> , 2, 73-88	12
1028	Combining targeted therapies. <b>2007</b> , 2, 241-252	1
1027	The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. <b>2007</b> , 60, 1-6	24
1026	ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study. <b>2008</b> , 110, 169-76	10
1025	EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. <b>2008</b> , 111, 321-7	19
1024	Targeted therapy for oesophageal cancer: an overview. <b>2008</b> , 27, 273-88	18
1023	Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling. <b>2008</b> , 13, 119-29	14
1022	The neuregulin family of genes and their multiple splice variants in breast cancer. <b>2008</b> , 13, 205-14	32
1021	ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. <b>2008</b> , 13, 235-46	69
1020	Amphiregulin as a novel target for breast cancer therapy. <b>2008</b> , 13, 171-9	39
1019	ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. <b>2008</b> , 13, 215-23	113

1018	HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. <b>2008</b> , 53, 3026-32	13
1017	Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas. <b>2008</b> , 26, 505-16	4
1016	The epidermal growth factor receptor family: biology driving targeted therapeutics. <b>2008</b> , 65, 1566-84	428
1015	Bisimulations in calculi modelling membranes. <b>2008</b> , 20, 351-377	20
1014	Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. <b>2008</b> , 37, 851-64	12
1013	Multimodality imaging of the HER-kinase axis in cancer. <b>2008</b> , 35, 186-208	94
1012	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. <b>2008</b> , 62, 605-20	29
1011	Can we predict the response to epidermal growth factor receptor targeted therapy?. <b>2008</b> , 3, 87-99	1
1010	Advanced non-small cell lung cancer therapy: historical and future perspectives. <b>2008</b> , 3, 135-147	2
1009	Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. <b>2008</b> , 3, 235-243	3
1008	A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer. <b>2008</b> , 70, 1707-29	18
1007	A mass action model of a Fibroblast Growth Factor signaling pathway and its simplification. <b>2008</b> , 70, 2229-63	7
1006	Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods. <b>2008</b> , 15, 65-72	20
1005	An update on the biology of cancer stem cells in breast cancer. <b>2008</b> , 10, 786-93	12
1004	AG825 increases radiosensitivity of breast cancer cell. <b>2008</b> , 7, 587-589	
1003	Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. <b>2008</b> , 8, 4383-401	86
1002	Quantitative phosphoproteomics by mass spectrometry: past, present, and future. <b>2008</b> , 8, 4433-43	144
1001	Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. <b>2009</b> , 5, 235-43	278

1000	Expression of G protein-coupled receptor kinase 4 is associated with breast cancer tumourigenesis. <b>2008</b> , 216, 317-27	17
999	Fmoc-based solid phase chemical synthesis of 71-meric neuregulin 1-beta1, an epidermal growth factor-like domain. <b>2008</b> , 14, 261-6	
998	Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. <b>2008</b> , 52, 815-22	43
997	Fucoidan from <i>Laminaria cichorioides</i> inhibits AP-1 transactivation and cell transformation in the mouse epidermal JB6 cells. <b>2008</b> , 47, 629-37	31
996	Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. <b>2008</b> , 113, 1453-61	78
995	Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy. <b>2008</b> , 73, 209-19	32
994	Pan-HER biologics (Hermodulins) for the treatment of cancer. <b>2008</b> , 69, 472-479	
993	Fungiform papilla pattern: EGF regulates inter-papilla lingual epithelium and decreases papilla number by means of PI3K/Akt, MEK/ERK, and p38 MAPK signaling. <b>2008</b> , 237, 2378-93	30
992	Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables. <b>2008</b> , 123, 1508-15	45
991	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. <b>2008</b> , 103, 624-35	38
990	Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. <b>2008</b> , 103, 1783-97	86
989	Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. <b>2008</b> , 104, 1124-49	140
988	The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis. <b>2008</b> , 105, 1147-52	22
987	The role of the EGFR signaling in tumor microenvironment. <b>2008</b> , 214, 559-67	280
986	Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. <b>2008</b> , 215, 827-36	29
985	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <b>2008</b> , 216, 698-707	29
984	Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. <b>2008</b> , 217, 409-22	70
983	Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. <b>2008</b> , 47, 633-8	10

982	Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. <b>2008</b> , 56, 1491-7	182
981	The development of HKI-272 and related compounds for the treatment of cancer. <b>2008</b> , 341, 465-77	123
980	Proteinarrays können Nebenwege von Tumor-Wirkstoffen im Brustkrebs aufdecken. <b>2008</b> , 38, 17-20	
979	Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. <b>2008</b> , 47, 1685-8	66
978	Heterobivalent Ligands Crosslink Multiple Cell-Surface Receptors: The Human Melanocortin-4 and $\mu$ Opioid Receptors. <b>2008</b> , 120, 1709-1712	7
977	3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors. <b>2008</b> , 26, 1169-78	13
976	Targeting the epidermal growth factor receptor in metastatic colorectal cancer. <b>2008</b> , 65, 8-20	33
975	The biological properties of cetuximab. <b>2008</b> , 68, 93-106	96
974	Towards predictive inhibitor design for the EGFR autophosphorylation activity. <b>2008</b> , 43, 781-91	5
973	Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. <b>2008</b> , 16, 7543-51	79
972	Quantitative measurement of epidermal growth factor receptor-mitogen-activated protein kinase signal transduction using a nine-plex, peptide-based immunoassay. <b>2008</b> , 375, 255-64	8
971	ErbB-directed immunotherapy: antibodies in current practice and promising new agents. <b>2008</b> , 116, 126-40	59
970	Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. <b>2008</b> , 32, 814-26	17
969	System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. <b>2008</b> , 15, 808-17	62
968	EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. <b>2008</b> , 15, 1193-201	48
967	Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. <b>2008</b> , 1130, 280-6	16
966	Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. <b>2008</b> , 9, 147-55	46
965	Establishment and characterization of a cell line (IGSK-3) secreting human chorionic gonadotropin, adrenocorticotrophic hormone and parathyroid hormone-related protein derived from primary poorly differentiated adenocarcinoma of the stomach. <b>2008</b> , 21, 88-94	1

964	STAT3 as a target for inducing apoptosis in solid and hematological tumors. <b>2008</b> , 18, 254-67	348
963	Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. <b>2008</b> , 21, 1168-75	66
962	The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. <b>2008</b> , 15, 1772-81	48
961	The ERBB3 receptor in cancer and cancer gene therapy. <b>2008</b> , 15, 413-48	174
960	Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. <b>2008</b> , 27, 339-46	108
959	Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. <b>2008</b> , 27, 3201-10	33
958	Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. <b>2008</b> , 9, 437-52	770
957	Par complex in cancer: a regulator of normal cell polarity joins the dark side. <b>2008</b> , 27, 6878-87	72
956	Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. <b>2008</b> , 27, 4315-23	35
955	MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. <b>2008</b> , 98, 1675-81	43
954	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. <b>2008</b> , 99, 341-9	72
953	Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. <b>2008</b> , 99, 1415-25	104
952	Epitope mapping of antibodies using bacterial surface display. <b>2008</b> , 5, 1039-45	77
951	Derailed endocytosis: an emerging feature of cancer. <b>2008</b> , 8, 835-50	548
950	Dynamic expression of Erbb pathway members during early mammary gland morphogenesis. <b>2008</b> , 128, 1009-21	23
949	Betacellulin regulates hair follicle development and hair cycle induction and enhances angiogenesis in wounded skin. <b>2008</b> , 128, 1256-65	27
948	Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. <b>2008</b> , 14, 308-10	4
947	Signaling pathways activated by epidermal growth factor receptor or fibroblast growth factor receptor differentially regulate branching morphogenesis in fetal mouse submandibular glands. <b>2008</b> , 50, 565-76	22

946	AllergoOncology: the role of IgE-mediated allergy in cancer. <b>2008</b> , 63, 1255-66	161
945	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <b>2008</b> , 41, 59-85	145
944	Signals and Systems: Towards a Systems Biology of Signal Transduction. <b>2008</b> , 96, 1386-1397	10
943	A co-culture system reveals the involvement of intercellular pathways as mediators of the lutropin receptor (LHR)-stimulated ERK1/2 phosphorylation in Leydig cells. <b>2008</b> , 314, 25-37	38
942	Endocytosis and intracellular trafficking of ErbBs. <b>2008</b> , 314, 3093-106	126
941	Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. <b>2008</b> , 314, 3415-25	43
940	The status and role of ErbB receptors in human cancer. <b>2008</b> , 84, 79-89	68
939	Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?. <b>2008</b> , 50, 2-22	51
938	A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. <b>2008</b> , 8, 169	60
937	Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. <b>2008</b> , 8, 227	21
936	Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. <b>2008</b> , 8, 305	78
935	tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). <b>2008</b> , 8, 377	88
934	HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. <b>2008</b> , 8, 38-49	36
933	Unraveling the biologic and clinical complexities of HER2. <b>2008</b> , 8, 392-401	77
932	Simulation of the regulation of EGFR endocytosis and EGFR-ERK signaling by endophilin-mediated RhoA-EGFR crosstalk. <b>2008</b> , 582, 2283-90	28
931	NF-kappa B-mediated adaptive resistance to ionizing radiation. <b>2008</b> , 44, 1-13	177
930	The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. <b>2008</b> , 1783, 896-903	45
929	Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. <b>2008</b> , 1785, 12-31	33

928	Agrin and neuregulin, expanding roles and implications for therapeutics. <b>2008</b> , 26, 187-201	9
927	Identification of the domain in ErbB2 that restricts ligand-induced degradation. <b>2008</b> , 20, 779-86	13
926	Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. <b>2008</b> , 591, 43-51	95
925	Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. <b>2008</b> , 12, 1527-34	81
924	Trophic factor expression in phrenic motor neurons. <b>2008</b> , 164, 252-62	27
923	Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. <b>2008</b> , 18, 244-50	175
922	ERBB receptors in developing, dysplastic and malignant oral epithelia. <b>2008</b> , 44, 227-35	40
921	Mechanism of activation and inhibition of the HER4/ErbB4 kinase. <b>2008</b> , 16, 460-7	132
920	Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy. <b>2008</b> , 59-77	
919	Comparison of the biodistribution and tumor targeting of two <sup>99m</sup> Tc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. <b>2008</b> , 49, 788-95	169
918	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. <b>2008</b> , 98, 418-25	303
917	The influence of HER2 genotypes as molecular markers on breast cancer outcome. <b>2008</b> , 27, 575-9	14
916	Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. <b>2008</b> , 121, 3155-66	27
915	Herceptin. <b>2008</b> , 183-219	52
914	HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. <b>2008</b> , 3, 1363-9	1
913	Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. <b>2008</b> , 62, 193-201	36
912	Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes. <b>2008</b> , 100, 281-90	25
911	Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. <b>2008</b> , 95, 2086-96	54

910	Promising newer molecular-targeted therapies in head and neck cancer. <b>2008</b> , 68, 1609-19	7
909	Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. <b>2008</b> , 7, 184-90	129
908	Medulloblastoma: what is the role of molecular genetics?. <b>2008</b> , 8, 1169-81	6
907	Clinical approaches to minimize rash associated with EGFR inhibitors. <b>2008</b> , 35, 103-11	17
906	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. <b>2008</b> , 2, 167-78	39
905	Erlotinib: the first biologic in the management of pancreatic cancer. <b>2008</b> , 9, 1595-607	8
904	Molecular targets and biological modifiers in gastric cancer. <b>2008</b> , 25, 274-87	23
903	Evolving options and future challenges for targeted therapies in ErbB2 (HER2)-positive breast cancer. <b>2008</b> , 6, 1-6	0
902	Receptor tyrosine kinase inhibitors in thyroid cancer. <b>2008</b> , 22, 1023-38	31
901	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <b>2008</b> , 6, 86-90	2
900	Structure-based view of epidermal growth factor receptor regulation. <b>2008</b> , 37, 353-73	236
899	Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. <b>2008</b> , 10, R2	113
898	The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. <b>2008</b> , 10, R9	72
897	Ovarian Cancer. <b>2008</b> ,	2
896	EGFR Signaling Networks in Cancer Therapy. <b>2008</b> ,	7
895	Single-molecule study of lateral mobility of epidermal growth factor receptor 2/HER2 on activation. <b>2008</b> , 112, 4140-5	28
894	Neurogenesis and Brain Repair. <b>2008</b> , 445-462	1
893	Molecular Biomethods Handbook. <b>2008</b> ,	10



892	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. <b>2008,</b>	2
891	Targeted Cancer Therapy. <b>2008,</b>	6
890	Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. <b>2008,</b> 102, 128-31	135
889	Mutations of the lutropin/choriogonadotropin receptor that do not activate the phosphoinositide cascade allow hCG to induce aromatase expression in immature rat granulosa cells. <b>2008,</b> 285, 62-72	16
888	ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. <b>2008,</b> 146, 43-8	11
887	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. <b>2008,</b> 376, 1388-402	118
886	Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. <b>2008,</b> 76, 15-22	42
885	Dimerization properties of the transmembrane domains of Arabidopsis CRINKLY4 receptor-like kinase and homologs. <b>2008,</b> 477, 219-26	11
884	ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. <b>2008,</b> 44, 831-54	134
883	EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. <b>2008,</b> 24, 27-33	9
882	Cellular roles of ADAM12 in health and disease. <b>2008,</b> 40, 1685-702	133
881	EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. <b>2008,</b> 263, 231-42	33
880	Multitargeted therapy of cancer by green tea polyphenols. <b>2008,</b> 269, 269-80	281
879	Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation. <b>2008,</b> 86, 322-34	24
878	Inhibitory effects of fucoidan on activation of epidermal growth factor receptor and cell transformation in JB6 Cl41 cells. <b>2008,</b> 46, 1793-800	62
877	Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. <b>2008,</b> 11, 110-21	141
876	Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. <b>2008,</b> 44, 419-26	32
875	Targeted therapies in breast cancer: where are we now?. <b>2008,</b> 44, 2781-90	71

874	N-glycan of ErbB family plays a crucial role in dimer formation and tumor promotion. <b>2008</b> , 1780, 520-4	46
873	FoxA1 as a lineage-specific oncogene in luminal type breast cancer. <b>2008</b> , 365, 711-7	49
872	Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking. <b>2008</b> , 371, 220-4	18
871	Molecular-targeted therapies: lessons from years of clinical development. <b>2008</b> , 34, 61-80	41
870	The epidermal growth factor receptor and its ligands in female reproduction: insights from rodent models. <b>2008</b> , 19, 173-81	32
869	Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. <b>2008</b> , 28, 269-81	35
868	Transcriptional networks inferred from molecular signatures of breast cancer. <b>2008</b> , 172, 495-509	12
867	Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. <b>2008</b> , 173, 14-24	128
866	Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. <b>2008</b> , 97, 4129-54	19
865	Correlation between expression of CXCR4 and prognosis in non-small cell lung cancer. <b>2008</b> , 1, 189-195	1
864	Molecular Genetics of Pancreatic Cancer. <b>2008</b> , 27-39	3
863	Domain-oriented reduction of rule-based network models. <b>2008</b> , 2, 342-51	39
862	System theoretical investigation of human epidermal growth factor receptor-mediated signalling. <b>2008</b> , 2, 273-84	28
861	Flow cytometric FRET analysis of ErbB receptor tyrosine kinase interaction. <b>2008</b> , Chapter 12, Unit12.14	0
860	The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. <b>2008</b> , 26, 136-44	7
859	A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. <b>2008</b> , 4, 643-53	51
858	EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. <b>2008</b> , 59, 429-42	120
857	Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. <b>2008</b> , 8, 319-29	9

856	EGF-like growth factors as LH mediators in the human corpus luteum. <b>2009</b> , 24, 176-84	35
855	Structure and clinical relevance of the epidermal growth factor receptor in human cancer. <b>2008</b> , 26, 1742-51	209
854	Implications of EGFR PharmDx kit for cetuximab eligibility. <b>2008</b> , 8, 141-8	15
853	Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing. <b>2008</b> , 4, 1151-9	24
852	Anti-epidermal growth factor receptor strategies for advanced breast cancer. <b>2008</b> , 26, 757-68	7
851	Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. <b>2008</b> , 47, 2518-30	94
850	HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. <b>2008</b> , 129, 263-73	111
849	Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers. <b>2008</b> , 47, 11992-2005	29
848	Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. <b>2008</b> , 47, 10314-23	81
847	Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. <b>2008</b> , 68, 9280-90	1193
846	Recognition-domain focused chemosensors: versatile and efficient reporters of protein kinase activity. <b>2008</b> , 130, 12821-7	80
845	The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. <b>2008</b> , 31, 809-19	87
844	The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. <b>2008</b> , 105, 6109-14	47
843	A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. <b>2008</b> , 283, 2031-41	123
842	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. <b>2008</b> , 283, 18393-401	138
841	Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. <b>2008</b> , 19, 4249-59	76
840	The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. <b>2008</b> , 283, 22885-9	116
839	Breast Cancer. <b>2008</b> ,	3

838	The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. <b>2008</b> , 26, 1778-80	15
837	t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. <b>2008</b> , 29, 1013-21	18
836	Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. <b>2008</b> , 6, 996-1002	39
835	Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. <b>2008</b> , 19 Suppl 7, vii281-8	3
834	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. <b>2008</b> , 13, 1166-76	39
833	Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. <b>2008</b> , 26, 2999-3005	277
832	Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. <b>2008</b> , 10, 675-89	84
831	A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. <b>2008</b> , 14, 2726-31	37
830	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. <b>2008</b> , 14, 6277-83	59
829	Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. <b>2008</b> , 7, 3223-36	24
828	CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. <b>2008</b> , 6, 446-57	110
827	MEKK3 initiates transforming growth factor beta 2-dependent epithelial-to-mesenchymal transition during endocardial cushion morphogenesis. <b>2008</b> , 103, 1430-40	23
826	Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. <b>2008</b> , 17, 1486-92	37
825	Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. <b>2008</b> , 14, 3956-65	26
824	Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. <b>2008</b> , 29, 299-306	31
823	Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. <b>2008</b> , 7, 935-43	17
822	Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. <b>2008</b> , 3, 258-64	48
821	ErbB4 targeting approaches for prostate cancer treatment. <b>2008</b> , 7, 1095-7	2

820	Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. <b>2008</b> , 23, 1733-41	51
819	Targeting growth factors in lung cancer. <b>2008</b> , 133, 1209-16	28
818	Neuregulin-1: a potential endogenous protector in perinatal brain white matter damage. <b>2008</b> , 93, 182-7	25
817	Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. <b>2008</b> , 3, 7-12	1
816	Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. <b>2008</b> , 19, 229-40	18
815	Overview of mimotopes and related strategies in tumor vaccine development. <b>2008</b> , 7, 1547-55	16
814	HER-2-positive metastatic breast cancer: trastuzumab and beyond. <b>2008</b> , 9, 2583-601	35
813	Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results. <b>2020</b> , 43, 895-901	7
812	Arid1a loss potentiates pancreatic $\beta$ cell regeneration through activation of EGF signaling.	1
811	Neuregulin-1 exerts molecular control over axolotl lung regeneration through ErbB family receptors.	3
810	Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. <b>2005</b> , 70, 483-8	7
809	Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. <b>2020</b> , 111, 3268-3278	5
808	BINDING SITE ANALYSIS OF THE NR4A NUCLEAR RECEPTOR NHR-6 DURING DEVELOPMENT. <b>2017</b> , 4,	1
807	ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy. <b>2016</b> , 76, 3659-62	10
806	The role of gefitinib in lung cancer treatment. <b>2004</b> , 10, 4233s-4237s	48
805	The biology of epidermal growth factor receptor in lung cancer. <b>2004</b> , 10, 4227s-4232s	183
804	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <b>2003</b> , 111, 1161-70	26
803	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <b>2003</b> , 111, 1161-1170	93

802	Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. <b>2005</b> , 115, 379-387	98
801	Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. <b>2005</b> , 115, 379-87	50
800	Host-based antipoxvirus therapeutic strategies: turning the tables. <b>2005</b> , 115, 231-3	14
799	Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. <b>2008</b> , 118, 3574-81	84
798	Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. <b>2009</b> , 119, 2702-13	71
797	Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. <b>2010</b> , 120, 2684-98	123
796	Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. <b>2011</b> , 121, 2242-53	231
795	Epidermal growth factor receptor inhibits colitis-associated cancer in mice. <b>2012</b> , 122, 2780-92	52
794	Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. <b>2013</b> , 123, 3459-71	49
793	Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas. <b>2020</b> , 16, 24	4
792	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. <b>2020</b> , 10, 21	4
791	Functional cross-talk between cytokine receptors revealed by activating mutations in the extracellular domain of the $\beta$ subunit of the GM-CSF receptor. <b>2002</b> , 72, 1246-1255	3
790	Functional Role of Membrane Lipids in EGF Receptor Dynamics and Regulation. <b>2014</b> , 41-58	1
789	MAPK3/1 is conducive to luteinizing hormone-mediated C-type natriuretic peptide decrease in bovine granulosa cells. <b>2016</b> , 62, 137-42	4
788	Modeling Cellular Noise Underlying Heterogeneous Cell Responses in the Epidermal Growth Factor Signaling Pathway. <b>2016</b> , 12, e1005222	19
787	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. <b>2008</b> , 3, e1592	45
786	HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. <b>2008</b> , 3, e2881	59
785	Regulation of ErbB2 receptor status by the proteasomal DUB POH1. <b>2009</b> , 4, e5544	35

784	Structure-function analysis of nucleolin and ErbB receptors interactions. <b>2009</b> , 4, e6128	24
783	Coupled stochastic spatial and non-spatial simulations of ErbB1 signaling pathways demonstrate the importance of spatial organization in signal transduction. <b>2009</b> , 4, e6316	23
782	Genetic dissection of epidermal growth factor receptor signaling during luteinizing hormone-induced oocyte maturation. <b>2011</b> , 6, e21574	80
781	EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. <b>2011</b> , 6, e23240	54
780	Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors. <b>2011</b> , 6, e23894	40
779	The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. <b>2011</b> , 6, e23936	35
778	A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. <b>2011</b> , 6, e24071	113
777	Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. <b>2011</b> , 6, e25301	30
776	Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. <b>2012</b> , 7, e31884	13
775	Monitoring the size and lateral dynamics of ErbB1 enriched membrane domains through live cell plasmon coupling microscopy. <b>2012</b> , 7, e34175	9
774	EGFR-mediated carcinoma cell metastasis mediated by integrin $\alpha 5 \beta 1$ depends on activation of c-Src and cleavage of MUC1. <b>2012</b> , 7, e36753	30
773	Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. <b>2012</b> , 7, e42805	39
772	Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. <b>2012</b> , 7, e50819	7
771	Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization. <b>2012</b> , 7, e51797	32
770	Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. <b>2013</b> , 8, e53510	12
769	Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells. <b>2013</b> , 8, e55657	12
768	ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice. <b>2013</b> , 8, e56282	19
767	Semi-supervised prediction of SH2-peptide interactions from imbalanced high-throughput data. <b>2013</b> , 8, e62732	22

766	Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. <b>2013</b> , 8, e64672	14
765	Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. <b>2013</b> , 8, e65113	46
764	Neuregulin upregulates microglial $\alpha 7$ nicotinic acetylcholine receptor expression in immortalized cell lines: implications for regulating neuroinflammation. <b>2013</b> , 8, e70338	27
763	Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. <b>2013</b> , 8, e75288	8
762	Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. <b>2013</b> , 8, e77270	61
761	HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. <b>2014</b> , 9, e98528	110
760	ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome. <b>2014</b> , 9, e105063	2
759	Functional aspects of the EGF-induced MAP kinase cascade: a complex self-organizing system approach. <b>2014</b> , 9, e111612	1
758	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. <b>2015</b> , 10, e0128360	13
757	Differential Expression of Hepatic Genes of the Greater Horseshoe Bat ( <i>Rhinolophus ferrumequinum</i> ) between the Summer Active and Winter Torpid States. <b>2015</b> , 10, e0145702	11
756	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. <b>2016</b> , 11, e0148101	22
755	Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. <b>2016</b> , 11, e0154430	5
754	MicroRNA Profiling in the Medial and Lateral Habenula of Rats Exposed to the Learned Helplessness Paradigm: Candidate Biomarkers for Susceptibility and Resilience to Inescapable Shock. <b>2016</b> , 11, e0160318	4
753	IgG-Containing Isoforms of Neuregulin-1 Are Dispensable for Cardiac Trabeculation in Zebrafish. <b>2016</b> , 11, e0166734	8
752	The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. <b>2017</b> , 12, e0171280	43
751	Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. <b>2017</b> , 12, e0177761	3
750	ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). <b>2017</b> , 12, e0177919	6
749	Sphingosine 1-Phosphate Activation of EGFR As a Novel Target for Meningitic <i>Escherichia coli</i> Penetration of the Blood-Brain Barrier. <b>2016</b> , 12, e1005926	28



748	Recent developments in receptor tyrosine kinases targeted anticancer therapy. <b>2016</b> , 9, 80-90	15
747	ECatenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer. <b>2018</b> , 41, 320-330	6
746	Zinc-dependent changes in oxidative and endoplasmic reticulum stress during cardiomyocyte hypoxia/reoxygenation. <b>2020</b> , 401, 1257-1271	4
745	ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. <b>2016</b> , 23, T243-T257	30
744	Kaempferol Downregulates Insulin-like Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells. <b>2014</b> , 19, 161-9	10
743	Kaempferol Downregulates Insulin-like Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells. <b>2014</b> , 19, 161-169	23
742	The improvement of anti-HER2 scFv soluble expression in Escherichia coli. 56,	5
741	Production and Characterization of Monoclonal Antibodies Against the Dimerization Domain of Human HER2. <b>2015</b> , 3,	1
740	Dynamic regulation of genetic pathways and targets during aging in Caenorhabditis elegans. <b>2014</b> , 6, 215-30	10
739	A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors. <b>2016</b> , 7, 148-53	6
738	HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. <b>2014</b> , 1, 196-204	18
737	Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. <b>2016</b> , 7, 55890-55899	23
736	Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. <b>2016</b> , 7, 53526-53539	5
735	Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. <b>2016</b> , 7, 57752-57762	2
734	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. <b>2017</b> , 8, 50570-50581	17
733	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. <b>2016</b> , 7, 54137-54156	18
732	Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. <b>2013</b> , 4, 1592-605	108
731	A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. <b>2016</b> , 7, 72167-72183	32

730	Identification of the zinc finger 216 (ZNF216) in human carcinoma cells: a potential regulator of EGFR activity. <b>2016</b> , 7, 74947-74965	2
729	Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. <b>2016</b> , 7, 79453-79473	13
728	Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. <b>2016</b> , 7, 81645-81660	10
727	Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. <b>2017</b> , 8, 6364-6375	4
726	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. <b>2017</b> , 8, 5160-5178	42
725	Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. <b>2017</b> , 8, 19923-19933	4
724	β2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. <b>2017</b> , 8, 29013-29027	29
723	Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines. <b>2017</b> , 8, 29846-29856	7
722	Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential. <b>2017</b> , 8, 35835-35847	7
721	Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion. <b>2017</b> , 8, 33745-33755	2
720	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <b>2017</b> , 8, 35193-35204	9
719	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <b>2017</b> , 8, 54444-54458	10
718	Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells. <b>2017</b> , 8, 60109-60122	5
717	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative F FDG-PET/CT metrics. <b>2017</b> , 8, 52792-52801	24
716	Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma. <b>2017</b> , 8, 74188-74208	14
715	Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway. <b>2017</b> , 8, 78351-78364	8
714	CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. <b>2014</b> , 5, 1969-86	48
713	Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and tumor growth in a highly tumorigenic ovarian cancer model. <b>2017</b> , 8, 55022-55038	8

712	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. <b>2017</b> , 8, 58847-58864	10
711	Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies. <b>2017</b> , 8, 82872-82884	2
710	ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. <b>2014</b> , 5, 5138-52	24
709	Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. <b>2018</b> , 9, 6463-6477	3
708	Erbin exerts a protective effect against inflammatory bowel disease by suppressing autophagic cell death. <b>2018</b> , 9, 12035-12049	11
707	BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. <b>2014</b> , 5, 11752-77	63
706	Targeted therapies for advanced non-small cell lung cancer. <b>2018</b> , 9, 37589-37607	36
705	A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors. <b>2015</b> , 6, 1286-301	4
704	Target HER four in breast cancer?. <b>2019</b> , 10, 3147-3150	4
703	Molecular architecture of the ErbB2 extracellular domain homodimer. <b>2015</b> , 6, 1695-706	32
702	Predicting response to HER2 kinase inhibition. <b>2015</b> , 6, 588-9	3
701	MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). <b>2015</b> , 6, 7454-69	19
700	ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. <b>2015</b> , 6, 9173-88	62
699	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. <b>2015</b> , 6, 5678-94	25
698	Swiprosin-1 stimulates cancer invasion and metastasis by increasing the Rho family of GTPase signaling. <b>2015</b> , 6, 13060-71	32
697	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. <b>2018</b> , 9, 24914-24926	15
696	The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways. <b>2015</b> , 6, 21865-77	22
695	Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor. <b>2015</b> , 6, 31628-39	2

694	Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo. <b>2015</b> , 6, 38912-25	28
693	The promise of anti-ErbB3 monoclonals as new cancer therapeutics. <b>2012</b> , 3, 744-58	70
692	HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. <b>2016</b> , 7, 473-89	18
691	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. <b>2016</b> , 7, 3068-83	17
690	Combination therapy of RY10-4 with the ß-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. <b>2016</b> , 7, 4142-54	11
689	EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma. <b>2016</b> , 7, 9017-25	13
688	Therapeutic siRNA for drug-resistant HER2-positive breast cancer. <b>2016</b> , 7, 14727-41	23
687	APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis. <b>2016</b> , 7, 21601-17	7
686	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. <b>2016</b> , 7, 27599-612	20
685	MUC1 stimulates EGFR expression and function in endometrial cancer. <b>2016</b> , 7, 32796-809	18
684	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. <b>2016</b> , 7, 52597-52612	31
683	HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. <b>2016</b> , 7, 51012-51026	22
682	Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.. <b>2019</b> , 2, 490-515	2
681	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. <b>2018</b> , 6, 160	17
680	Role of erlotinib in the management of pancreatic cancer. <b>2006</b> , 2, 435-45	13
679	MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. <b>2013</b> , 20, 2486-99	20
678	Nanotherapeutics for the Treatment of Cancer and Arthritis. <b>2019</b> , 20, 430-445	7
677	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <b>2019</b> , 19, 595-630	17

676	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. <b>2020</b> , 20, 815-834	64
675	An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. <b>2020</b> , 20, 2599-2633	5
674	Development and Validation of an LC-MS/MS Method for Quantitative Determination of EAI045, A Novel EGFR Inhibitor, in Rat Plasma. <b>2020</b> , 16, 273-279	1
673	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <b>2019</b> , 14, 242-257	2
672	New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. <b>2019</b> , 19, 2156-2176	2
671	EGF Mediates Survival of Rat Cochlear Sensory Cells via an NF- $\kappa$ B Dependent Mechanism In Vitro. <b>2008</b> , 2, 9-15	8
670	Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness. <b>2009</b> , 2, 1-5	20
669	Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways. <b>2018</b> , 19, 2255-2262	4
668	The EGFR expression in gastric mucosa of children infected with Helicobacter pylori. <b>2009</b> , 54, 187-93	2
667	Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <b>2012</b> , 52, 131-135	1
666	Chemotherapy and metastatic breast cancer. <b>2006</b> , 41-68	1
665	DARPinS: Promising Scaffolds for Theranostics. <b>2019</b> , 11, 42-53	23
664	The Role of Interleukin-37 in the Pathogenesis of Allergic Diseases. <b>2019</b> , 11, 54-64	5
663	Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. <b>2006</b> , 16, 179-93	20
662	Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. <b>2013</b> , 20, 303-17	17
661	Emerging therapies in gastrointestinal cancers. <b>2006</b> , 12, 7440-50	18
660	Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?. <b>2007</b> , 13, 5877-87	32
659	Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study. <b>2012</b> , 18, 6447-51; discussion p.6450	2

658	Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. <b>2013</b> , 19, 2883-93	28
657	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <b>2016</b> , 22, 6345-61	69
656	Changing strategies for target therapy in gastric cancer. <b>2016</b> , 22, 1179-89	29
655	HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. <b>2016</b> , 22, 7926-37	32
654	Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. <b>2016</b> , 22, 2284-93	35
653	Glucocorticoid receptor regulates expression of microRNA-22 and downstream signaling pathway in apoptosis of pancreatic acinar cells. <b>2018</b> , 24, 5120-5130	9
652	[Role of HER2 in NSCLC]. <b>2015</b> , 18, 644-51	1
651	Overexpression of HER2/HER3 and clinical feature of ovarian cancer. <b>2019</b> , 30, e75	21
650	Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways. <b>2020</b> , 22, 3994-4002	1
649	Neuregulin 1 enhances cell adhesion molecule L1 like expression levels and promotes malignancy in human glioma. <b>2020</b> , 20, 326-336	3
648	Analysis of Her2/neu Overexpression and Amplification in Urothelial Carcinoma of the Bladder Associated with Cox-2 overexpression. <b>2010</b> , 7, 8-24	3
647	Receptor tyrosine kinase structure and function in health and disease. <b>2015</b> , 2, 476-502	6
646	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. <b>2016</b> , 3, 386-416	1
645	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). <b>2011</b> , 3, 57-64	15
644	Molecular biology of lung cancer. <b>2013</b> , 5 Suppl 5, S479-90	120
643	Markers of resistance to anti-EGFR therapy in colorectal cancer. <b>2013</b> , 4, 308-18	35
642	Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. <b>2016</b> , 7, 173-80	3
641	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). <b>2013</b> , 2, 128-41	11

640	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. <b>2015</b> , 4, 36-54	389
639	The significance of genetics for cholangiocarcinoma development. <b>2013</b> , 1, 28	16
638	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. <b>2014</b> , 2, 122	27
637	A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscle. <b>2015</b> , 3, 249	4
636	Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?. <b>2016</b> , 4, 80	6
635	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. <b>2011</b> , 19, 371-389	6
634	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. <b>2019</b> , 18, 5	2
633	Epidermal Growth Factor Receptor as Predicting Factor on Biochemical Recurrence after Radical Prostatectomy: A Prospective Study. <b>2008</b> , 49, 974	6
632	Mechanisms Mediating the Synergistic Anticancer Effects of Combined Erlotinib and Celecoxib Treatment. <b>2011</b> , 3, 1-7	21
631	Endometrial Carcinogenesis and Molecular Signaling Pathways. <b>2014</b> , 04, 134-149	14
630	Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer. <b>2011</b> , 02, 675-682	3
629	Hypersensitive Inhibition of the Proliferation of Cells with Mutated DNA Repair-Related Genes by the Catalytic Topoisomerase II Inhibitor 20-O-IngenolE2. <b>2012</b> , 03, 158-165	1
628	HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy. <b>2015</b> , 05, 106-128	3
627	Mucins in neoplasms of pancreas, ampulla of Vater and biliary system. <b>2016</b> , 8, 725-734	20
626	Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines. <b>2014</b> , 6, 653-62	21
625	Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. <b>2014</b> , 5, 806-23	19
624	Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. <b>2010</b> , 43, 91-6	35
623	YAC tripeptide of epidermal growth factor promotes the proliferation of HaCaT keratinocytes through activation of EGFR. <b>2014</b> , 47, 581-6	4

622	Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells. <b>2015</b> , 48, 342-7	7
621	Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. <b>2010</b> , 154, 281-8	16
620	Regulation of tumor cell migration by protein tyrosine phosphatase (PTP)-proline-, glutamate-, serine-,and threonine-rich sequence (PEST). <b>2013</b> , 32, 75-83	15
619	In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy. <b>2019</b> , In Press,	3
618	Extracellular HSP90 in Cancer Invasion and Metastasis: From Translational Research to Clinical Prospects. <b>2015</b> , 4, 178-190	1
617	Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. <b>2019</b> , 17, 194-200	3
616	Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target. <b>2018</b> , 14, 482-487	3
615	Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer. <b>2019</b> , 15, 287-294	4
614	Networking of predicted post-translational modification (PTM) sites in human EGFR. <b>2019</b> , 15, 448-456	2
613	Tyrosine kinase - Role and significance in Cancer. <b>2004</b> , 1, 101-115	283
612	Trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes. <b>2013</b> , 1, 10	3
611	Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF- $\beta$ and TGF- $\beta$ . <b>2013</b> , 14, 6813-20	25
610	B-cell Lymphoma 2 rs17757541 C>G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. <b>2013</b> , 14, 4301-6	8
609	Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. <b>2014</b> , 15, 5343-8	13
608	Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases. <b>2015</b> , 16, 6445-9	7
607	Molecular basis for multimerization in the activation of the epidermal growth factor receptor. <b>2016</b> , 5,	91
606	Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. <b>2019</b> , 8,	12
605	A Multifunctional Controller Realized by Biochemical Reactions. <b>2015</b> , 8, 99-107	2



604	Computational Evaluation of Bioactive Compounds from Schott as a Novel EGFR Inhibitor for Cancer Treatment. <b>2021</b> , 20, 11769351211049244	1
603	Insilco Design and Potential Cytotoxic agents EGFR Inhibitors of 4(3H) Quinazolinone Derivatives. <b>2021</b> , 4849-4855	
602	Fusion of apoptosis-related protein Cytochrome c with anti-HER-2 single-chain antibody targets the suppression of HER-2+ breast cancer. <b>2021</b> , 25, 10638-10649	3
601	The membrane-linked adaptor FRS2 $\beta$ fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis. <b>2021</b> , 118,	2
600	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <b>2021</b> , 40, 313	2
599	Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesaemia: Is There a Best Replacement Strategy?.	
598	Redundant roles of EGFR ligands in the ERK activation waves during collective cell migration. <b>2022</b> , 5,	1
597	Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy. <b>2021</b> , 21, 1491-1507	2
596	Dual Kinase Inhibition of EGFR/HER2: Design, Synthesis and Molecular Docking of Thiazolopyrazolyl-Based Aminoquinoline Derivatives as Anticancer Agents**. <b>2021</b> , 6, 11012-11021	1
595	DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. <b>2021</b> ,	1
594	Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. <b>2021</b> , 12, 868-881	1
593	Rôle des facteurs de croissance dans la plasticité des pithéliums au cours du développement et dans la carcinogénèse. <b>2001</b> , 185, 1279-1294	
592	Protéolyse membranaire : le clivage de ErbB-4 permet sa migration vers le noyau. <b>2002</b> , 18, 404-406	
591	Protein Tyrosine Kinase Receptor Signaling Overview. <b>2003</b> , 391-396	1
590	HER2 and Topoisomerase II $\beta$ in Breast Carcinoma. <b>2004</b> , 261-283	
589	HER-2/neu Gene Copy Number Quantified by Real-Time PCR in Cell Lines and Breast Cancer Tissue. <b>2004</b> , 107-116	
588	Applications of Optical Biosensors to Structure-Function Studies on the EGF/EGF Receptor System. <b>2004</b> , 133-164	
587	Exploring Membrane Microdomains and Functional Protein Clustering in Live Cells with Flow and Image Cytometric Methods. <b>2004</b> , 99-120	

- 586 The Potential of EGFR-Targeted Agents in Cancer Prevention. **2004**, 317-324 1
- 585 Growth Factor Signaling Pathways in Cancer. **2004**, 267-315
- 584 Cellular Oncogenes and Carcinogenesis. **2005**, 103-129
- 583 Transcriptional Profiling of Peripheral Blood in Oncology. **2005**, 47-63
- 582 A Novel Anti-EGFR Monoclonal Antibody, Cetuximab (Erbiximab®). **2006**, 46, 267-275
- 581 ErbB family. **2006**, S128-S128
- 580 Cancer chemotherapy. **2007**, 718-735 1
- 579 Is There a Role for ErbB Dual Kinase Inhibition?. **2007**, 203-212
- 578 Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. **2007**, 213-234
- 577 Cardiac Development: Molecular and Genetic Analysis. **2007**, 117-163
- 576 Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer. **2007**, 81-96
- 575 Signal Transduction Inhibitors, HER Family, EGFR Inhibition, and Clinical Achievements. **2007**, 31-56
- 574 Pan-HER Inhibitors. **2007**, 67-76
- 573 What is cancer?. **2007**, 1-16 0
- 572 The role of ErbB3 N-glycan in dimer formation: Implications for transforming activity. **2008**, 20, 219-225
- 571 Cellular sensitivity to EGF receptor inhibitors. **2008**, 340-355
- 570 A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions. **2008**, 2008, 253-255
- 569 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365

568 The intersection of EGFR and the Ras signaling pathway. **2008**, 84-90

567 EGFR family heterodimers in cancer pathogenesis and treatment. **2008**, 14-29

3

566 Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. **2008**, 103-126

565 Fundamentals of Cancer Cell Biology and Molecular Targeting. **2008**, 1933-1945

564 EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. **2008**, 281-324

563 Natural Agents That Can Sensitize Tumor Cells to Chemotherapy and Radiation Therapy. **2008**, 211-240

3

562 Signaling Networks in Biology. 1

561 Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. **2008**, 080808065800257-24

560 Metastasis of hormone receptor positive breast cancer. **2009**, 147, 1-22

559 Targeting Signaling Pathways in Cancer Therapy. **2009**, 309-326

558 Molecular Pathology of Breast Cancer. **2009**, 360-378

557 Growth Factor Receptor Signaling and Metastasis of Oral Cancer. **2009**, 185-196

556 Expression Profiles of Retinoblastoma Protein and p27Kip1 According to HER2 Amplification Status in Primary Breast Cancer. **2009**, 12, 14

555 A Molecular Mechanism of Diminished Binding Activity between 15 bp Deletion Mutant EGFR and c-Cbl Ubiquitin Ligase. **2009**, 55-66

554 Kutane Nebenwirkungen unter Therapie mit EGFR-Inhibitoren. **2009**, 248-251

553 BREAST CANCER. **2009**, 933-944

552 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2009**, 287-303

551 Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights. **2009**, 1, 72

1

- 550 EGFR Signaling Pathways in Pancreatic Cancer Pathogenesis. **2010**, 387-402
- 549 Clinicopathologic Significances of EGFR Expression at Invasive Front of Colorectal Cancer. **2010**, 44, 16
- 548 Les facteurs de croissance et les r cepteurs   activit  tyrosine kinase. **2010**, 21-43
- 547 Role of Lipid Domains in EGF Receptor Signaling. **2010**, 359-364
- 546 The Role of Oncogene Activation in Tumor Progression. **2010**, 19-41
- 545 Monoclonal Antibody Therapy.
- 544 Prostate Cancer. **2010**, 386-402
- 543 Kinase-mediated quasi-dimers of EGFR. **2010**, 24, 4744-4755 3
- 542 Epidermal Growth Factor Receptor-Targeted Therapies. **2011**, 305-333
- 541 Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forward in the Era of Molecularly Targeted Therapy. **2011**, 165-187
- 540 Neoplasms of Extrahepatic Bile Ducts. **2011**, 881-890
- 539 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461
- 538 Pertuzumab   HER-2 Dimerisation Inhibitor  for the Treatment of Breast and Other Cancers. **2011**, 73-90
- 537 References. **2011**, 249-347
- 536 Translational Research in Lung Cancer. **2011**, 793-808
- 535 Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. **2011**, 1-31
- 534 The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. **2011**, 33-53
- 533 Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. **2011**, 329-366

532 Novel Quinazoline Derivatives Targeting on EGFR Kinase Mediated Signal Pathway in A431 Human Epidermoid Carcinoma Cells. **2011**, 21, 349-357

531 In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. 121102072334007

530 Targeting HER2+and trastuzumab-resistant metastatic breast cancer. **2011**, 035-049

529 Oesophago-Gastric Cancer. **2012**, 221-244

1

528 ErbB Membrane Tyrosine Kinase Receptors: Analyzing Migration in a Highly Complex Signaling System. **2012**, 105-131

527 ASSOCIATION BETWEEN GROWTH FACTOR HEREGULIN -1<sup>α</sup>; AND RECEPTORS IN GROWTH OF OVARIAN CANCER CELL LINE WITH HIGH POTENTIALITY OF PERITONEAL DISSEMINATION. **2012**, 58, 22-32

526 Efficacy of primed in situ labelling in determination of HER-2 gene amplification and CEN-17 status in breast cancer tissue. **2012**, 13, 329-37

525 Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. **2012**, 03, 902-911

524 Breast Cancer. **2012**, 195-219

523 Colorectal Cancer. **2012**, 245-272

522 Endocytic Regulation of EGFR Signaling. **2012**, 4, 3.1-3.7

521 Targeted Prostate Cancer Chemoprevention Trial with Tocotrienols. **2012**, 101-116

520 ADAMs in Cancer. 299-324

519 Target Therapy in Inflammatory Breast Cancer. **2013**, 119-127

518 Molecular Pathology of Lung Cancers. **2013**, 83-94

517 Growth Factor Receptor Signaling, DNA Damage Response, and Cancer Cell Susceptibility to Chemotherapy and Relapses. **2013**, 45-74

0

516 Cortactin and EGFR Proteins Expression in Egyptian Patients with Non-small Cell Lung Carcinoma. **2012**, 9, 24-35

515 Prerequisite Genetic Traits for Metastasis. **2013**, 403-444

514 EGFR, Immunology. **2013**, 1-10

513 HER2-Positive Metastatic Breast Cancer: Second-Line Treatment. **2013**, 61-74

512 Introduction and Background Biology. **2013**, 1-12

511 EGFR, Growth Factors. **2013**, 1-11

510 Stress-Driven Endocytosis of Tyrosine-Phosphorylated EGFR Leads to Tumorigenesis: The Critical Role of Oxidative Stress. **2013**, 303-325

509 Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice. **2013**, 04, 1005-1017

508 Resistance to Anticancer Antibodies: From Mechanisms to Solutions. **2013**, 1-24

507 Emerging Targeted Agents for HER2-Positive Breast Cancer. **2013**, 75-96

506 Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. **2013**, e2-e11

1

505 Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. **2013**, 3, 10.1-10.8

504 Monoclonal antibodies targeting EGFR/HER2 and clinical outcomes in cancer treatment. **2013**, 2-8

503 Tumors of the skin, the CNS and the head and neck. **2013**, 72-89

502 Gynecologic cancers. **2013**, 90-105

501 The Human Epidermal Growth Factor Receptor 2 (HER2). **2014**, 23-33

0

500 Molecular Pathology and Diagnostics of Gynecologic Malignancies. **2014**, 365-395

499 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118

498 Epidermal Growth Factor Receptor Inhibitor Reactions. 184-195

497 Endometrial Cancer.

1

496 Lens Epithelial Cell Proliferation. **2014**, 59-80

495 Molecular Targeted Therapy of Head and Neck Cancer: Promising Molecular Targets of Post-Epidermal Growth Factor Receptor Era. **2014**, 57, 575

494 Intracellular Signaling. **2014**, 22-39.e8

493 Rol biológico y aplicaciones de los miRNAs en cáncer de seno. **2014**, 16, 188

492 Single-molecule optical methods analyzing receptor tyrosine kinase activation in living cells. **2015**, 1233, 35-44

1

491 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2015**, 285-302

1

490 ? Targeting Growth Factor Receptors for Radiosensitization. **2014**, 346-387

489 HER3. **2015**, 1-19

488 Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine. **2015**, 39-55

487 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. **2015**, 381-412

486 The EGFR/ERBB Receptor Family. **2015**, 107-164

0

485 Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. **2015**, 119-136

484 Neoplasia of the Gastrointestinal Tract. 587-616

483 HER2-positive metastatic breast cancer: second-line treatment. **2016**, 71-86

482 Diversity and implication of MAPK signal transduction involved in the regulation of chemotherapy-induced DNA damage response. **2016**, 303-328

481 A Stability Analysis Method for Biochemical Reaction System with Inhibitory Feedback Loop. **2016**, 136, 617-624

480 Emerging targeted agents for HER2-positive breast cancer. **2016**, 87-110

479 Introduction and background biology. **2016**, 1-13

- 478 Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through activation of the EGFR/AKT pathway. **2016**, 62, 476-486
- 477 Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. **2016**, 168, 393-479
- 476 Crosstalk Mechanisms Following Targeted Therapy in Head and Neck Cancer. **2016**, 59, 181
- 475 Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors. **2016**, 9, e4022 4
- 474 - Gene Body Methylation and Transcriptional Regulation: Statistical Modelling and More. **2016**, 225-243
- 473 High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes.
- 472 Novel Cancer Therapies Targeting Angiogenesis. **2017**, 197-202
- 471 Oncogenes and the Initiation and Maintenance of Tumorigenesis. **2017**, 143-157
- 470 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726
- 469 Small Molecule Inhibitors. **2017**, 771-795
- 468 Studies on Arsenic and Human Health. **2017**, 37-66
- 467 Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. **2017**, 1-31
- 466 Machine learning identifies SNPs predictive of advanced coronary artery calcium in ClinSeq<sup>®</sup> and Framingham Heart Study cohorts.
- 465 Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues. **2017**, In Press, 1
- 464 Flies to Humans - Humans to Flies: A Virtuous Circle of Colorectal Cancer Prevention. 047-060
- 463 Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells. **2017**, 55, 491-503 2
- 462 HER-2 ONCOPROTEIN EXPRESSION IN UROTHELIAL CARCINOMA. **2017**, 6, 5985-5990
- 461 Contact inhibitory Eph signaling suppresses EGF-promoted cell migration by decoupling EGFR activity from vesicular recycling. 0



460 HER-2/NEU EXPRESSION IN STOMACH AND GASTRO-OESOPHAGEAL JUNCTION CARCINOMA IN ENDOSCOPIC BIOPSY SPECIMENS. **2017**, 6, 6123-6126

459 Expression of EGF receptors in canine prostate with proliferative inflammatory atrophy and carcinoma. **2017**, 47, 1

458 Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. **2017**, 5, 57-63

457 Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal.

456 The role of C-terminal tensin-like (Cten) gene in cancer metastasis. 2-9 1

455 Quantitative super-resolution single molecule microscopy dataset of YFP-tagged growth factor receptors.

454 Targeted therapy in cancer. **2018**, 3, 13

453 Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites.

452 An In-Vivo Investigation of the Cardio-Protective Potential of Aspirin, Ebestradiol and Calcipotriol for Trastuzumab Treatment of Her-2 Positive Breast Cancer. **2018**, 11, 123-139

451 Interdependence of EGFR with PTPs on juxtaposed membranes generates a growth factor sensing and responding network.

450 EGF signalling in epithelial carcinoma cells utilizes preformed receptor homoclusters, with larger heteroclusters post activation.

449 Adjuvant Therapy for HER2-Positive Early-Stage Breast Cancer. **2019**, 383-411

448 Clathrin-coated Pits are Shredded Organelles Presorting Receptors in the Plasma Membrane.

447 Breast Cancer. **2019**, 241-269

446 Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors. **2019**, 15, 1574-1580

445 Pathological analysis of ErbB family and NRG-1 protein in progressive supranuclear palsy. **2019**, 70, 13-17

444 Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. **2019**, 143-161

443 Cytotoxicity of Sodium Arsenite-loaded Anti-HER2 Immunoliposomes Against HER2-expressing Human Breast Cancer Cell Lines. **2019**, 16, 556-562

- 442 DEAD-box protein family member DDX28 is a negative regulator of HIF-2 $\beta$  and eIF4E2-directed hypoxic translation.
- 441 HER2 Cancer Protrusion Growth Signaling Regulated by Unhindered, Localized Filopodial Dynamics. 1
- 440 Cell-to-cell diversification in ERBB-RAS-MAPK signal transduction that produces cell-type specific growth factor responses.
- 439 Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.
- 438 A DNA nanoassembly-based approach to map membrane protein nanoenvironments.
- 437 Kinase activity of ERBB3 contributes to intestinal organoids growth and intestinal tumorigenesis. **2020**, 111, 137-147 6
- 436 Current Perspectives in Human Papilloma Virus: Where We are and What We Need?. **2019**, 12, 1683-1700 1
- 435 Development of HER2-targeted Therapies for Gastrointestinal Cancer. **2020**, 16, 29
- 434 Actualidades en el manejo sistémico del cáncer de mama. **2020**, 10, 71-82
- 433 The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. **2020**, 5, 048-053 1
- 432 Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. **2020**, 164, 127-132
- 431 Expression and clinical significance of microRNA-21, PTEN and p27 in cancer tissues of patients with non-small cell lung cancer. **2020**, 20, 49 2
- 430 Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. **2021**, 11, 731535 6
- 429 Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. **2021**, 1 1
- 428 *Fusobacterium nucleatum* facilitates cetuximab resistance in colorectal cancer via the PI3K/AKT and JAK/STAT3 pathways. 0
- 427 Drug Targets for Biologics. **2020**, 71-88
- 426 Embryonic lethality and defective mammary gland development of activator-function impaired conditional knock-in *ErbB3V943R* mice. **2021**, 2, e10036
- 425 A Janus-like DNA probe kit for simultaneously imaging the homo- and heterodimerization of HER2 and HER3 on living tumor cells. **2022**, 350, 130872 0

- 424 Proteinase imbalance in oral cancer and other diseases. **2022**, 165-208 0
- 423 Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings. **2020**, 63, S123-S128 1
- 422 New analysis pipeline for high-throughput domain-peptide affinity experiments improves SH2 interaction data.
- 421 Molecular and Signaling Pathways During Oral Carcinogenesis. **2020**, 179-194 1
- 420 Transient Commensal Clonal Interactions Can Drive Tumor Metastasis.
- 419 Mathematical modelling of Her2 (ErbB2) PI3K/AKT signalling pathways during breast carcinogenesis to include PTPD2. **2020**, 5, 4946-4958
- 418 Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous delivery of tyrosine kinase inhibitors and kinase activity biosensors. **2021**, 13, 18520-18535 0
- 417 Osteopontin expression and its relationship with prognostic biomarkers in canine mammary carcinomas. **2020**, 40, 210-219
- 416 Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer. 1
- 415 Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. 0
- 414 Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes. **2021**, 22, 0
- 413 HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. **2021**, 10, 8808 4
- 412 Regulation of NRG-1-ErbB4 signaling and neuroprotection by exogenous neuregulin-1 in a mouse model of epilepsy. **2021**, 161, 105545
- 411 Working together for the family: determination of HER oncogene co-amplifications in breast cancer. **2020**, 11, 2774-2792
- 410 Gene expression profiling of hepatocellular carcinoma: past, present and future. 233-237
- 409 Les nouvelles cibles thérapeutiques. Les nouvelles thérapeutiques ciblées. **2006**, 233-266
- 408 Para- und autokrine Aspekte der Pathogenese des duktaalen Pankreaskarzinoms: Einfluss von Zytokinen und Wachstumsfaktoren. **2006**, 309-321
- 407 Maligne Tumoren der Pankreas und der periampullären Region. **2006**, 501-529

406 Molecular Staging of Non-Small-Cell Lung Cancer. **2006**, 159-176

2

405 Novel Targets for Lung Cancer Therapy. **2006**, 419-429

404 Signal transduction inhibitors. **2006**, 185-199

403 Endocrine therapy of breast cancer. **2006**, 201-230

402 Patterning by EGF Receptor: Models from Drosophila Development. **2006**, 333-353

401 Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. **2008**, 291-306

400 The Seed of Selfishness. **2008**, 9-26

399 Response and Resistance to Ionizing Radiation. **2006**, 507-529

398 The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. **2007**, 335-357

397 Intercellular Targets of Prostate Cancer. **2007**, 475-486

396 The Cell Cycle. **2008**, 3-32

395 Employing Systems Biology to Quantify Receptor Tyrosine Kinase Signaling in Time and Space. **2007**, 300-318

394 Targeted Drug Therapy in Pancreatic Cancer. **2008**, 271-287

393 Autres traitements ciblés (trastuzumab exclu). **2007**, 453-498

392 Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. **2006**, 643-670

391 Innovative Rational-Derived, Target-Based and Cytotoxic Therapies for Breast Cancer and Other Malignancies. **2006**, 741-780

390 Tiermodelle in der biomedizinischen Forschung. **2008**, 207-241

389 Structural and dynamic characterization of the C-terminal tail of ErbB2: disordered but not random.

388	Origin of diverse phosphorylation patterns in the ERBB system.	
387	INVESTIGATION OF NEUREGULIN-1 GEN rs6994992 POLYMORPHISM IN GIFTED STUDENTS.	
386	Functional Annotation of Genes of Predisposition to Schizophrenia and Celiac Disease. <b>2020</b> , 56, 1246-1251	1
385	Apicobasal surfaceome architecture encodes for polarized epithelial functionality and depends on tumor suppressor PTEN.	
384	A general technique for the detection of switch-like bistability in chemical reaction networks governed by mass action kinetics with conservation laws.	
383	Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. <b>2007</b> , 3, 871-6	20
382	Decoding human liver cancer signatures. <b>2008</b> , 2, S31-4	
381	Cetuximab in the management of colorectal cancer. <b>2007</b> , 1, 77-91	12
380	The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. <b>2009</b> , 14, e62-7	8
379	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. <b>2007</b> , 2, 81-8	1
378	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. <b>2010</b> , 36, 19-27	4
377	Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. <b>2011</b> , 4, 403-9	3
376	Urothelial carcinomas: a focus on human epidermal receptors signaling. <b>2011</b> , 3, 362-73	27
375	Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. <b>2011</b> , 16, 70-4	77
374	The Role of EGFR and HER2- Activating Mutations in Maxillary Sinus Cancer. <b>2012</b> , 7, 70-4	1
373	RNA aptamers and their therapeutic and diagnostic applications. <b>2013</b> , 4, 27-40	56
372	HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. <b>2006</b> , 26, 4235-43	47
371	Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. <b>2013</b> , 1, 10	2

- 370 The interaction of the ErbB4 intracellular domain p80 with  $\beta$ -enolase in the nuclei is associated with the inhibition of the neuregulin1-dependent cell proliferation. **2014**, 5, 21-9 3
- 369 Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer. **2014**, 7, 1459-64
- 368 Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. **2011**, 4, 1-35 5
- 367 Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways. **2014**, 7, 6438-46 26
- 366 Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. **2014**, 4, 776-88 4
- 365 Development and characterization of <sup>89</sup>Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. **2013**, 12, 17-27 38
- 364 Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers. **2015**, 7, 39-52 10
- 363 Inhibition of 4-nitroquinoline-1-oxide-induced oral carcinogenesis by dietary calcium. **2015**, 8, 3529-42 6
- 362 Association between ErbB3 genetic polymorphisms and coronary artery disease in the Han and Uyghur populations of China. **2015**, 8, 16520-7 2
- 361 A perspective on anti-EGFR therapies targeting triple-negative breast cancer. **2016**, 6, 1609-23 115
- 360 Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?. **2017**, 11, 43-48 5
- 359 MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma. **2017**, 9, 5332-5346 8
- 358 Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. **2018**, 10, 4183-4192 4
- 357 miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR). **2019**, 11, 4151-4165 13
- 356 Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. **2019**, 9, 2103-2119 31
- 355 Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. **2020**, 12, 923-939 3
- 354 GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. **2020**, 10, 3705-3720 4
- 353 [Research Progress of Targeted Therapy for HER2 Gene ?in Advanced Non-small Cell Lung Cancer]. **2020**, 23, 1108-1112

352	A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. <b>2021</b> , 11, 2867-2892	1
351	Proteomics and its applications in breast cancer. <b>2021</b> , 11, 4006-4049	
350	[Neuregulin 2 is highly expressed in glioma tissues to regulate glial fibrillary acidic protein expression Akt signaling]. <b>2021</b> , 41, 1171-1176	
349	Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. <b>2021</b> , 15, 101265	1
348	Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature. <b>2021</b> , 19, 330	0
347	Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling.. <b>2021</b> , 10,	15
346	Clathrin adapters AP-1 and GGA2 support expression of epidermal growth factor receptor for cell growth. <b>2021</b> , 10, 80	1
345	NAAA is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. <b>2021</b> ,	1
344	The Role of EREG/EGFR Pathway in Tumor Progression. <b>2021</b> , 22,	6
343	HER3 is an Actionable Target in Advanced Prostate Cancer. <b>2021</b> ,	2
342	Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs. <b>2021</b> , 11,	0
341	Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study. <b>2021</b> , 27, 361	1
340	A narrative review of liver regeneration-from models to molecular basis.. <b>2021</b> , 9, 1705	0
339	A Bispecific Antibody Targeting HER2 and PD-L1 Inhibits Tumor Growth with Superior Efficacy. <b>2021</b> , 101420	4
338	Expresi3n de receptores hormonales como factor predictivo de respuesta al tratamiento en pacientes con c3ncer de mama temprano y localmente avanzado con sobreexpresi3n de HER2 en un hospital privado. <b>2021</b> , 66, 258-262	
337	Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development.. <b>2021</b> , 34,	1
336	Vaccination against Her-2/neu, with focus on peptide-based vaccines.. <b>2022</b> , 7, 100361	1
335	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. <b>2004</b> , 6, 12-21	1

334	Mass spectrometric detection of KRAS protein mutations using molecular imprinting. <b>2021</b> ,	2
333	Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients.. <b>2022</b> , 29, 10732748211068963	
332	LncRNAs, the Molecules Involved in Communications With Colorectal Cancer Stem Cells.. <b>2022</b> , 12, 811374	0
331	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.. <b>2022</b> , 134, 63	0
330	Evaluation of fluorine-18-fluorodeoxyglucose PET/computed tomography and human epithelial growth factor receptor 2 expression in treatment-naive patients with lung adenocarcinoma.. <b>2022</b> , 43,	
329	Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article).. <b>2022</b> , 1	1
328	Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.. <b>2022</b> , 12, 4	0
327	Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer.. <b>2021</b> , 12, 803304	6
326	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.. <b>2022</b> , 21, 28	22
325	Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.. <b>2022</b> , 27, 245-250	0
324	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. <b>2022</b> , 27,	5
323	Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib.. <b>2022</b> ,	1
322	EGFR-Targeted Photodynamic Therapy.. <b>2022</b> , 14,	6
321	The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.. <b>2022</b> , 74, 18-47	0
320	Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection.. <b>2022</b> , 121, 105585	
319	A numerical approach for detecting switch-like bistability in mass action chemical reaction networks with conservation laws.. <b>2022</b> , 23, 1	3
318	ZC3H15 promotes glioblastoma progression through regulating EGFR stability.. <b>2022</b> , 13, 55	0
317	Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.. <b>2022</b> , 14,	1



316	Role of EGF Receptor Regulatory Networks in the Host Response to Viral Infections.. <b>2021</b> , 11, 820355	1
315	Influence of Anoctamin-4 and -9 on ADAM10 and ADAM17 Sheddase Function.. <b>2022</b> , 12,	1
314	Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.. <b>2022</b> , 22, 7	0
313	AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression.. <b>2022</b> , 24, 1	0
312	Reciprocal EGFR signaling in the anchor cell ensures precise inter-organ connection during <i>Caenorhabditis elegans</i> vulval morphogenesis.. <b>2022</b> , 149,	0
311	In vitro and in vivo evaluation of a novel anti-EGFR antibody labeled with 89Zr and 177Lu. <b>2022</b> , 331, 747	0
310	ADAM17 regulates p75-mediated fibrinolysis and nerve remyelination.. <b>2022</b> ,	0
309	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.. <b>2022</b> ,	8
308	Origin of diverse phosphorylation patterns in the ERBB system.. <b>2021</b> ,	
307	Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer.. <b>2022</b> , 18, 101355	1
306	Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.. <b>2022</b> ,	1
305	Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.. <b>2022</b> , 1	1
304	A novel dual-labeled small peptide as a multimodal imaging agent for targeting wild-type EGFR in tumors.. <b>2022</b> , 17, e0263474	1
303	HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma.. <b>2021</b> , 12, 831318	
302	Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements.. <b>2022</b> ,	8
301	Phosphoproteome of signaling by ErbB2 in ovarian cancer cells.. <b>2022</b> , 140768	0
300	Integrated Analysis of circRNA-miRNA-mRNA ceRNA Network in Cardiac Hypertrophy.. <b>2022</b> , 13, 781676	1
299	Shifting the Focus of Signaling Abnormalities in Colon Cancer.. <b>2022</b> , 14,	0

298	EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.. <b>2022</b> , 1	1
297	prediction of ErbB signal activation from receptor expression profiles through a data analytics pipeline. <b>2018</b> , 43, 295-306	1
296	Evaluation of human epidermal growth factor receptor 2 expression in colorectal cancer and its correlation with clinicopathological variables. <b>2021</b> , 26, 103	
295	Modeling the Cluster Size Distribution of Vascular Endothelial Growth Factor (VEGF) Receptors.. <b>2022</b> , 16, 11779322221085078	
294	Biomarkers in muscle invasive bladder cancer.. <b>2022</b> , 107, 265-297	0
293	CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.. <b>2022</b> , 18, 2609-2626	2
292	A radiologist's guide to novel anticancer therapies in the era of precision medicine.. <b>2022</b> , 9, 100406	0
291	Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer.. <b>2022</b> , 12, 2928	0
290	Targeting RPS6K1 for Refractory Breast Cancer Therapy.	
289	Dual-Targeted Self-Assembled DNA Hydrogels Decorated With Multivalent Aptamers Loaded With DOX for Anticancer Therapy.. <b>2022</b> , 13, 807498	3
288	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.. <b>2022</b> , 24, 475	0
287	Emerging Role of Oxidative Stress on EGFR and OGG1-BER Cross-Regulation: Implications in Thyroid Physiopathology.. <b>2022</b> , 11,	0
286	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.. <b>2022</b> , 12, 834104	1
285	Nanobodies as molecular imaging probes.. <b>2022</b> ,	0
284	Recombinant Prolidase Activates EGFR-Dependent Cell Growth in an Experimental Model of Inflammation in HaCaT Keratinocytes. Implication for Wound Healing.. <b>2022</b> , 9, 876348	1
283	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.. <b>2022</b> , 14,	1
282	Structure-activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR.. <b>2022</b> ,	
281	Interrelated Oncogenic Viruses and Breast Cancer.. <b>2022</b> , 9, 781111	1

280	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. <b>2022</b> , 12, 869672	3
279	Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.. <b>2022</b> , 79, 178	0
278	68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET. 1	
277	Metastatic urothelial carcinoma harboring mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report.. <b>2022</b> , 10, 2497-2503	0
276	Pharmacological Modulation of Apoptosis and Autophagy in the Treatment of Pancreatic Cancer.. <b>2022</b> ,	0
275	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.. <b>2022</b> , 23, 12	0
274	A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression.. <b>2022</b> , 17, 217-224	
273	Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.. <b>2022</b> , 23,	0
272	EGFR Signaling in Lung Fibrosis.. <b>2022</b> , 11,	3
271	Analysis of the epidermal growth factor receptor/phosphoinositide-dependent protein kinase-1 axis in tumor of the external auditory canal in response to epidermal growth factor stimulation.	
270	MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.. <b>2022</b> , 20, 27	0
269	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.. <b>2022</b> , 3, 8	5
268	Epidermal Growth Factor Pathway in the Age-Related Decline of Oligodendrocyte Regeneration.. <b>2022</b> , 16, 838007	1
267	F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs.. <b>2022</b> , 14,	0
266	Role of NRF2 in Ovarian Cancer.. <b>2022</b> , 11,	7
265	Synthesis and evaluation of novel HER-2 inhibitors to exert anti-breast cancer ability through epithelial-mesenchymal transition (EMT) pathway.. <b>2022</b> , 237, 114325	0
264	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.. <b>2022</b> , 15, 331-343	0
263	HER2 targeted therapy in colorectal cancer: New horizons.. <b>2022</b> , 105, 102363	2

262	Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.. <b>2022</b> , 10,	1
261	Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: A review of phase II and III trials.. <b>2022</b> ,	0
260	Cascade Downregulation of HER Family by a Dual-Targeted Recombinant Protein-Drug Conjugate to Inhibit Tumor Growth and Metastasis.. <b>2022</b> , e2201558	1
259	Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis.. <b>2022</b> , 25, 104211	0
258	Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm.. <b>2022</b> ,	4
257	Obesity phenotype induced by high-fat diet leads to maternal-fetal constraint, placental inefficiency, and fetal growth restriction in mice.. <b>2022</b> , 108977	
256	PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland.. <b>2021</b> , 14,	2
255	Epitope Mapping of an Anti-HER2 Monoclonal Antibody (HMab-181) Using Enzyme-Linked Immunosorbent Assay.. <b>2021</b> , 40, 255-260	0
254	The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.. <b>2021</b> ,	4
253	HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy.. <b>2021</b> , 14,	1
252	EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.. <b>2021</b> , 11, 766659	2
251	Integration of Genomic Profiling and Organoid Development in Precision Oncology.. <b>2021</b> , 23,	
250	Analysis of changes of cavity volumes in predefined directions of protein motions and cavity flexibility.. <b>2021</b> ,	
249	Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.. <b>2021</b> , 15, 5135-5150	0
248	The Visualization of Protein-Protein Interactions in Breast Cancer: Deployment Study in Pathological Examination.. <b>2021</b> , 54, 177-183	1
247	Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.. <b>2021</b> , 8, 800945	0
246	A Non-Canonical Function of Arabidopsis ERECTA Proteins in Gibberellin Signaling.	
245	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. <b>2021</b> , 61, 911-918	

- 244 A toolkit for recombinant production of seven human EGF family growth factors in active conformation.. **2022**, 12, 5034 0
- 243 Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.. **2022**, OF1-OF11 1
- 242 Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice. **2022**, 29, 2941-2953 0
- 241 EGFR signaling pathway as therapeutic target in human cancers.. **2022**, 1
- 240 A Novel Caenorhabditis elegans Gene Network Uncovers Mechanisms of Mitochondrial Maintenance.
- 239 Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy. **2005**, 531-552
- 238 Data\_Sheet\_1.PDF. **2020**,
- 237 Data\_Sheet\_2.PDF. **2020**,
- 236 Data\_Sheet\_1.docx. **2019**,
- 235 Image\_1.tiff. **2020**,
- 234 Image\_2.tiff. **2020**,
- 233 Image\_3.tiff. **2020**,
- 232 Image\_1.tif. **2020**,
- 231 Table\_1.doc. **2020**,
- 230 Table\_2.doc. **2020**,
- 229 Image\_1.PNG. **2019**,
- 228 Image\_1.TIF. **2019**,
- 227 table\_1.PDF. **2018**,

226	Data_Sheet_1.PDF. <b>2018,</b>	
225	CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression.. <b>2022,</b>	2
224	Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR and EGFR.. <b>2022,</b> 37, 1196-1211	5
223	Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer.. <b>2022,</b>	2
222	CSN6: a promising target for cancer prevention and therapy. <b>2020,</b> 35, 645-652	1
221	A phase III trial of alpelisib + trastuzumab + fulvestrant versus trastuzumab + chemotherapy in HER2+ -mutated breast cancer.. <b>2022,</b>	0
220	[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer ?with Epidermal Growth Factor Receptor Gene Mutation].. <b>2022,</b> 25, 183-192	
219	Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.. <b>2022,</b> 29, 10732748221099230	0
218	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer.. <b>2022,</b> 14,	0
217	No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients—A 10-Year Follow-Up Study in the Polish Population. <b>2022,</b> 13, 729	0
216	A Case of Isolated Myeloid Sarcoma Associated With Germline T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels.. <b>2022,</b> 11, 71-76	
215	ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth.. <b>2022,</b> 39, 64	0
214	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.. <b>2022,</b> 13, 2526	1
213	Preliminary evaluation and in vitro cytotoxicity studies of [ <sup>131</sup> I]-trastuzumab in HER2 expressing ovarian cancer cells.	1
212	FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.. <b>2022,</b> 1	0
211	Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis. <b>2022,</b> 14, 2379	0
210	Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini Review.. <b>2022,</b>	
209	Role of the epidermal growth factor receptor in thrombin regulated vascular smooth muscle cells proliferation. <b>2013,</b> 47, 10-20	

208	Herstatin, an Autoinhibitor of the Epidermal Growth Factor (EGF) Receptor Family, Blocks the Intracranial Growth of Glioblastoma. <b>2005</b> , 11, 335-340	7
207	Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. <b>2004</b> , 3, 1335-1342	17
206	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.. <b>2022</b> , 42, 1-14	0
205	ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer.. <b>2022</b> , 12, 8112	0
204	Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation.. <b>2022</b> ,	
203	Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. <b>2022</b> , 12,	0
202	Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis.	0
201	Impact of the HER2 Expression on Survival and Fluorouracil-Based Adjuvant Chemotherapeutic Benefits in Stage II/III Gastric Cancer: A Multicenter Observational Study.	
200	Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review. <b>2022</b> , 102418	1
199	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. <b>2022</b> , 16, 117955492211032	0
198	Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. <b>2022</b> , 27, 3844	0
197	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. <b>2022</b> , 23, 6806	2
196	Effects of Spore-Displayed p75 Protein from Lacticaseibacillus rhamnosus GG on the Transcriptional Response of HT-29 Cells. <b>2022</b> , 10, 1276	1
195	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. <b>2022</b> , 11, 1195	0
194	The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples. <b>2022</b> , 14, 3074	
193	Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. Publish Ahead of Print,	0
192	Evaluation of Paecilomyces tenuis producing Huperzine A for the management of root-knot nematode Meloidogyne incognita (Nematoda: Meloidogynidae).	0
191	Covalent Hemin/G4 complex-linked sandwich bioassay on magnetic beads for femtomolar HER-2/neu detection in human serum via direct electrocatalytic reduction of oxygen. <b>2022</b> , 1219, 340049	0

190	Emerging trends in immunotoxin targeting cancer stem cells. <b>2022</b> , 83, 105417	2
189	New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study. <b>2022</b> , 127, 105966	1
188	Aquaporins in Cancer Biology. 12,	1
187	Biosimilar monoclonal antibodies in China: A patent review. <b>2022</b> , 13, 14503-14518	
186	Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models. <b>2022</b> , 14, 1338	0
185	ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells. <b>2022</b> , 23, 7127	1
184	A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. <b>2022</b> , 39,	1
183	A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers.	0
182	P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR. <b>2022</b> , 14, 3243	
181	Research progress in targeted therapy and immunotherapy for gastric cancer. Publish Ahead of Print,	1
180	Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors. 28,	0
179	Breast cancer brain metastasis: Current evidence and future directions.	0
178	Stimulatory effects of TGF $\beta$ in granulosa cells of bovine small antral follicles. <b>2022</b> , 100,	0
177	Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. <b>2022</b> , 12,	
176	Specific nanomarkers fluorescence in vitro analysis for EGFR overexpressed cells in triple-negative breast cancer and malign glioblastoma. <b>2022</b> , 102997	2
175	Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. <b>2022</b> , 147, 105787	1
174	Shedding light on HER4 signaling in normal and malignant breast tissues. <b>2022</b> , 97, 110401	0
173	Discovery and evaluation of cytosine N-isoflavones as novel EGFR/HER2 dual inhibitors. <b>2022</b> , 127, 105868	0



172	Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line. <b>2005</b> , 65, 473-482	119
171	Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. <b>2004</b> , 3, 459-463	20
170	The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer. <b>2005</b> , 65, 18-25	33
169	Gene Identification and Potential Drug Therapy for Drug-Resistant Melanoma with Bioinformatics and Deep Learning Technology. <b>2022</b> , 2022, 1-13	0
168	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. <b>2022</b> , 14, 3674	0
167	Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance. <b>2022</b> , 13,	0
166	Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. <b>2022</b> , 31, 1401-1413	
165	Cell Proliferation Receptor-Enhanced 3D High-Throughput Screening Model for Optimized Drug Efficacy Evaluation in Breast Cancer Cells.	1
164	Biologics in rectal cancer. 1-13	
163	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. <b>2022</b> , 14, 3996	2
162	Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis. <b>2022</b> , 9, e000719	0
161	Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.	
160	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).	4
159	Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy.	1
158	Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews. <b>2022</b> , 14, 3834	1
157	Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.	2
156	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).	39
155	Uncovering Streptomyces-Derived Compounds as Cosmeceuticals for the Development of Improved Skin Photoprotection Products: An In Silico Approach to Explore Multi-Targeted Agents. <b>2022</b> , 90, 48	

154	HERIZON-GEA-01: Zanidatamab + chemo + tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.	2
153	Patched-Related Is Required for Proper Development of Embryonic Drosophila Nervous System. 16,	
152	The diverse functions of FAT1 in cancer progression: good, bad, or ugly?. <b>2022</b> , 41,	2
151	Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells. <b>2022</b> , 31, 101326	
150	Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF- $\kappa$ B signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells. <b>2022</b> , 99, 110433	1
149	Structural, spectroscopic and quantum chemical analysis of an exocyclic extended double-bonded chalcone single crystal, with pharmaceutical scanning for breast cancer using MCF-7 cell line and EGFR domain target. <b>2022</b> , 1270, 133849	
148	HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer. <b>2022</b> , 28, 339-345	2
147	Effects of <i>Alkanna bracteosa</i> extract on the expression level of HSP90 $\alpha$ and HER2 genes in human gastric cancer cell line.	0
146	First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinoma in routine clinical practice-results from A Subgroup Analysis.	0
145	Molecular mechanisms by which targeted muscle reinnervation improves the microenvironment of spinal cord motor neurons and target muscles. <b>2022</b> , 789, 136879	0
144	Understanding the Molecular Kinetics in NSCLC Through Computational Method. <b>2022</b> , 129-163	0
143	The protein corona reduces the anticancer effect of graphene oxide in HER-2-positive cancer cells. <b>2022</b> , 4, 4009-4015	1
142	Translational Research in Lung Cancer. <b>2022</b> ,	0
141	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. <b>2022</b> , 14, 175883592211117	0
140	Clinical Significance of Neuregulin 4, Afamin, and SERPINB1 in Gestational Diabetes Mellitus and Their Relationship with Insulin Resistance. <b>2022</b> , 2022, 1-8	0
139	Neuregulin-1, a potential therapeutic target for cardiac repair. 13,	0
138	Regulation of Signaling from the Epidermal Growth Factor Family.	0
137	Regulation of Signaling from the Epidermal Growth Factor Family. <b>2022</b> , 126, 7475-7485	0

136	Can EGFR be a therapeutic target in breast cancer?. <b>2022</b> , 1877, 188789	1
135	Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma.	2
134	One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis. 13,	0
133	Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity.	0
132	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13,	2
131	Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.	0
130	Detecting and monitoring bladder cancer with exfoliated cells in urine. 12,	0
129	Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. <b>2022</b> , 14, 1654-1664	0
128	HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives. <b>2022</b> , 10,	0
127	Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. 9,	0
126	Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents.	0
125	Revealing the Therapeutic Targets and Mechanism of Ginsenoside Rg1 for Liver Damage Related to Anti-Oxidative Stress Using Proteomic Analysis. <b>2022</b> , 23, 10045	1
124	Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. 12,	2
123	Imaging strategies for receptor tyrosine kinase dimers in living cells.	0
122	The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle. <b>2022</b> , 576, 83-95	0
121	Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines. <b>2022</b> , 3, 100132	0
120	Photo-induced synthesis and antitumor activity of marine zygosporamide analogs containing the isoindolinone fragment.	0
119	TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-B. <b>2022</b> , 14, 4809	1

- 118 Functional Diversity of Neuronal Cell Adhesion and Recognition Molecule L1CAM through Proteolytic Cleavage. **2022**, 11, 3085 ○
- 117 Cellular context alters EGF-induced ERK dynamics and reveals potential crosstalk with GDF-15. **2022**, 16, 054104 ○
- 116 Hallmarks of Cancer Expression in Oral Lichen Planus: A Scoping Review of Systematic Reviews and Meta-Analyses. **2022**, 23, 13099 ○
- 115 Evaluation of cell-cell interaction methods by integrating single-cell RNA sequencing data with spatial information. **2022**, 23, ○
- 114 Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. **2022**, 14, 5160 1
- 113 HB-EGF upregulates StAR expression and stimulates progesterone production through ERK1/2 signaling in human granulosa-lutein cells. **2022**, 20, ○
- 112 Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. **2022**, 14, 4859 ○
- 111 Signaling pathways and therapeutic interventions in gastric cancer. **2022**, 7, ○
- 110 High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. 12, ○
- 109 An Approach to the Simultaneous Determination of a Panel of Five Biomarkers for the Early Detection of Brain Cancer Using the Stochastic Method. **2022**, 4, 1382-1394 ○
- 108 Overexpression of ErbB-1 (EGFR) Protein in Eutopic Endometrium of Infertile Women with Severe Ovarian Endometriosis during the Implantation Window of Menstrual Cycle. **2022**, 3, 280-296 ○
- 107 Clinicopathological features and prognosis of patients with HER2-low breast cancer. ○
- 106 Ursodeoxycholic acid inhibits epithelial-mesenchymal transition, suppressing invasiveness of bile duct cancer cells: An in vitro study. **2022**, 24, ○
- 105 Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study. **2022**, 101, e30922 ○
- 104 Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel activity by suppressing the NF-κB signaling pathway. 12, ○
- 103 PEGylated Strontium Sulfite Nanoparticles with Spontaneously Formed Surface-Embedded Protein Corona Restrict Off-Target Distribution and Accelerate Breast Tumour-Selective Delivery of siRNA. **2022**, 13, 211 ○
- 102 Escape from the HER2-activated DCIS-like state is skewed by divergent nucleocytoplasmic transport. ○
- 101 Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. **2022**, 103863 ○

100	Arid1a loss potentiates pancreatic βcell regeneration through activation of EGF signaling. <b>2022</b> , 41, 111581	0
99	PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.	0
98	Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer. <b>2022</b> , 65, 100884	0
97	PUF60 promotes glioblastoma progression through regulation of EGFR stability. <b>2022</b> , 636, 190-196	0
96	Computer-Aided Screening and Revealing Action Mechanism of Food-Derived Tripeptides Intervention in Acute Colitis. <b>2022</b> , 23, 13471	0
95	5D-QSAR studies of 1H-pyrazole derivatives as EGFR inhibitors. <b>2022</b> , 28,	0
94	A high-quality chromosome-level genome assembly of Pelteobagrus vachelli provides insights into its environmental adaptation and population history. 13,	0
93	Molecular Mechanisms of Breast Cancer Metastasis.	0
92	Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling. <b>2022</b> ,	1
91	Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum.	0
90	Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. <b>2022</b> , 14, 5456	0
89	An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma. <b>2022</b> , 23, 13497	0
88	Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. <b>2022</b> , 86, 104352	0
87	Non-small-cell lung cancer-associated gene mutations and inhibitors. <b>2022</b> , 6, 100076	0
86	Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. <b>2022</b> , 14, 2494	0
85	Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.	0
84	Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. <b>2023</b> , 1869, 166618	1
83	AREG upregulates secreted protein acidic and rich in cysteine expression in human granulosa cells. <b>2023</b> , 561, 111826	0

- 82 Curcumin based pyrazole-thiazole hybrids as antiproliferative agents: Synthesis, pharmacokinetic, photophysical properties, and docking studies. **2023**, 1275, 134633 ○
- 81 Salivary non-apoptotic tumoral microvesicles: A potential progressive marker in oral cancer patients. **2022**, 26, 5955-5965 ○
- 80 The role of miR-488-3p on suppressing colorectal cancer by Codonopsis Bulleyana Forest ex Diels in mice. ○
- 79 Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. **2022**, 14, 5678 ○
- 78 Transcriptome Analysis Reveals Immunomodulatory Effect of Spore-Displayed p75 on Human Intestinal Epithelial Caco-2 Cells. **2022**, 23, 14519 ○
- 77 Prostate cancer expressing membrane-bound TGF- $\beta$  induces bone formation mediated by the autocrine effect of prostaglandin E2 in osteoblasts. **2022**, ○
- 76 Steric Hindrance OnDiff Mass-Tagged Probe Set Enables Detection of Protein Homodimer in Living Cells. **2022**, 14, 54517-54526 ○
- 75 Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity. **2022**, 479, 2465-2475 ○
- 74 Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers. **2022**, 12, 1880 ○
- 73 Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. 12, 1 ○
- 72 Apicobasal Surfaceome Architecture Encodes for Polarized Epithelial Functionality and Depends on Tumor Suppressor PTEN. **2022**, 23, 16193 ○
- 71 A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. **2022**, 11, 4093 ○
- 70 Integrating Network Pharmacology Approaches to Decipher the Multi-Target Pharmacological Mechanism of Microbial Biosurfactants as Novel Green Antimicrobials Against Listeriosis. **2023**, 12, 5 2
- 69 Fluorescent in situ hybridization is a deceptive method for screening NRG1 gene rearrangements. ○
- 68 Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes. 10, ○
- 67 Correlation of Shear-Wave Elastography and Apparent Diffusion Coefficient Values in Breast Cancer and Their Relationship with the Prognostic Factors. **2022**, 12, 3021 ○
- 66 Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor. **2022**, 23, 15828 ○
- 65 Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. **2022**, 3, ○

- 64 Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer. **2023**, 15, 554 ○
- 63 IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy. 10, ○
- 62 A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma. ○
- 61 Antibody-drug conjugates in lung cancer: dawn of a new era?. **2023**, 7, 3 ○
- 60 Recombinant Human Prolidase (rhPEPD) Induces Wound Healing in Experimental Model of Inflammation through Activation of EGFR Signalling in Fibroblasts. **2023**, 28, 851 ○
- 59 MOTS-c and aerobic exercise induce cardiac physiological adaptation via NRG1/ErbB4/CEBP $\beta$  modification in rats. **2023**, 315, 121330 ○
- 58 A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. **2023**, 40, ○
- 57 Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives. **2023**, 16, 43 ○
- 56 Mechanisms of drug resistance in HCC. Publish Ahead of Print, ○
- 55 Information-transfer characteristics in network motifs. **2023**, 5, ○
- 54 Structure and dynamics of the EGFR/HER2 heterodimer. ○
- 53 High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. **2023**, 18, e0280507 ○
- 52 Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis. **2023**, 22, 153303382211503 ○
- 51 YAP/TAZ-mediated resistance to EGFR inhibitors. **2023**, 37-53 ○
- 50 Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence. **2023**, 145, 2711-2732 ○
- 49 Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. **2023**, 41-46 ○
- 48 MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS-mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. **2023**, 145-150 ○
- 47 CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. **2023**, 14, ○

- 46 Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2. **2023**, 34, 101436 ○
- 45 Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. **2023**, 11, 662 ○
- 44 Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. **2023**, 18, ○
- 43 The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. **2023**, 170, 172-178 ○
- 42 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 ○
- 41 The Future of AntibodyDrug Conjugates in Urothelial Cancer. **2023**, 3, 137-159 ○
- 40 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452 ○
- 39 Regulation mechanism and functional verification of key functional genes regulating muscle development in black Tibetan sheep. **2023**, 868, 147375 ○
- 38 A herbal product inhibits carbon tetrachloride-induced liver fibrosis by suppressing the epidermal growth factor receptor signaling pathway. **2023**, 311, 116419 ○
- 37 MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY. 1413-1443 ○
- 36 Monoclonal antibodies in breast cancer: A critical appraisal. **2023**, 183, 103915 ○
- 35 Her2low breast cancer. New opportunities and challenges. **2022**, 30, 62-74 ○
- 34 The role of amphiregulin in ovarian function and disease. **2023**, 80, ○
- 33 Targeting Breast Cancer: An Overlook on Current Strategies. **2023**, 24, 3643 ○
- 32 Structure and dynamics of the EGFR/HER2 heterodimer. **2023**, 9, ○
- 31 Unlocking cardiomyocyte renewal potential for myocardial regeneration therapy. **2023**, 177, 9-20 ○
- 30 HER Receptor, Current, and Emerging Therapeutic Targets. **2023**, 1-32 ○
- 29 Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis. 13, ○



- 28 3D Stochastic Microsensors Based on Single-Walled Carbon Nanotubes Decorated with Gold Nanoparticles for Molecular Recognition and Determination of Heregulin- $\beta$  and HER Family (HER1 $\beta$ ) in Biological Samples. **2023**, 170, 037503
- 27 Nrf2 and Her3 co-expression in cholangiocarcinoma: Possible biological pathways for potential therapeutic approach. **2023**,
- 26 Liquid Application Dosing Alters the Physiology of Air-Liquid Interface Primary Bronchial Epithelial Cultures and In Vitro Testing Relevant Endpoints.
- 25 Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer. **2023**, 335-353
- 24 Cancer-associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?. **2023**, 47, 859-893
- 23 Collectin-11 promotes cancer cell proliferation and tumor growth. **2023**, 8,
- 22 A cell-based subtractive panning strategy for selection of conformation-specific single-chain variable-fragment (scFv) against dimerization domain of EGFR. **2023**, 515, 113456
- 21 Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. 13,
- 20 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32
- 19 An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. **2023**, 14,
- 18 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987
- 17 Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study. **2023**, 28, 3014
- 16 Combined physicochemical and functional assessment of pertuzumab integrity supports extended in-use stability.
- 15 Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook. **2023**, 19, 109-119
- 14 Mecanismos de resistencia al trastuzumab. **2023**, 17,
- 13 Precision Oncology Targets in Biliary Tract Cancer. **2023**, 15, 2105
- 12 Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors.
- 11 The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996

- 10 Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach. 1-27 ○
- 9 Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state. **2023**, 14, ○
- 8 Electrochemical Cellulase-Linked ELASA for Rapid Liquid Biopsy Testing of Serum HER-2/neu. ○
- 7 [Review of HER2 overexpression and somatic mutations in cancers](#) **2023**, 103997 ○
- 6 Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. **2023**, 12, 1156 ○
- 5 Detailed curriculum vitae of HER2-targeted therapy. **2023**, 245, 108417 ○
- 4 Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status. 14, ○
- 3 Bioinformatics analysis combined with molecular dynamics simulation validation to elucidate the potential molecular mechanisms of Jianshen Decoction for treatment of osteoporotic fracture. **2023**, 102, e33610 ○
- 2 The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. **2023**, 9, ○
- 1 A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer. 1-9 ○